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ABSTRACT 
 
Julie Marie Sullivan: Effects of Small Molecule Binding to mRNA on Gene Expression 
(Under the direction of H. Holden Thorp) 
   
RNA plays significant roles in many cellular processes and exhibits attractive features 
for use as a small molecule targeted therapeutic.  This study focuses on using RNA as a drug 
target, specifically investigating the process by which small molecules can regulate gene 
expression through their interaction with secondary structural elements found in the 5’ 
untranslated region (UTR) of two cellular messenger RNA (mRNA) targets, human ferritin 
and human preproinsulin. 
Previous work has identified compounds that specifically and selectively bind in the 
hairpin loop of the iron responsive element (IRE) in human ferritin mRNA using a chemical 
footprinting method.  Ferritin is regulated at the translational level by IRP binding to the IRE, 
preventing assembly of the translational initiation complex.  One small molecule, promazine, 
was identified that binds to an internal bulge in the IRE sequence where an iron regulatory 
protein (IRP) binds.  The binding site identified during the initial screening was confirmed 
through an enzymatic footprinting assay.  Using an electrophoretic mobility shift assay, we 
have shown that this compound can disrupt the binding of IRP proteins to the IRE sequence.  
In an in vitro translation assay, binding of promazine leads to up-regulation of ferritin protein 
synthesis by greater than 60% while showing no effect on control mRNA. 
 iii 
The 5’UTR of the human preproinsulin mRNA exists in two forms, the native form, 
and a splice variant which is up-regulated in response to chronic glucose stimulation.  Small 
molecules were screened for their ability to bind to, or change the secondary structure of, the 
5’UTR of the preproinsulin mRNAs using RNase cleavage, and the transition metal cleavage 
agents Ru(tpy)(bpy)O2+ (RuO2+, bpy = 2,2’-bipyridine, tpy = 2,2’,2’’-terpyridine), and 
Ru(bpy)32+.  Two small molecules, neomycin B and kanamycin B, have been identified as 
binding to the mRNAs using these screening methods.  Binding of neomycin B, and 
kanamycin B decreased the amount of preproinsulin protein synthesized for both the native 
and splice variant forms in an in vitro translation assay.  A decrease in the translation of a 
control RNA was also seen, indicating that the binding of these aminoglycosides are not 
specific to secondary structures found in preproinsulin mRNA.     
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 Chapter 1 
Introduction: Targeting RNA with Small Molecules 
 
1.1 RNA as a Drug Target 
 Expression of the numerous genes in a cell must be tightly regulated to provide 
appropriate levels of RNA and protein production at all times.  The cell must interpret many 
different chemical and physical signals in order to respond to environmental and cellular 
needs.  Organisms make extensive use of protein-based control systems to regulate gene 
expression; modulating mechanisms of transcription, translation, and mRNA processing or 
degradation.  RNA is essential for transcriptional and translational regulation, protein 
function, and catalysis.  These recently discovered functions of RNA dramatically expand its 
role in the cell and highlight the potential of targeting RNA for the treatment of a number of 
disease states.   
Currently, most small molecule drug discovery efforts are focused on proteins 
involved in biological pathways associated with disease, although more emphasis is being 
placed on targeting small molecules to RNA.  The unique structures formed by RNA are 
thought to provide suitable binding pockets for small molecules,1 and most small molecules 
that target RNA have been shown to selectively bind to noncanonically paired regions.2  
Over the next two chapters, my work will focus on investigating the use of small molecules 
to modulate gene expression through their interaction with structured regulatory elements 
found in messenger RNA (mRNA).  
 2 
 RNA is an attractive therapeutic target because of its many functions in the cell and 
its lack of a cellular repair mechanism.3-5  RNA also provides a target for drugs where a 
protein target is unavailable or inaccessible, as is seen in many viral6,7 and bacterial targets.8-
10  Drugs which bind to mRNA structures involved in post-transcriptional regulation can 
either up- or down-regulate expression of a gene.  Up-regulation of gene expression is not 
often accomplished in protein targeting because drugs are normally used to inhibit protein 
function.11  The ability of small molecules such as the macrolide and aminoglycoside 
antibiotics to interact with bacterial ribosomal RNA has been known for some time, and have 
set a precedent for targeting structured domains of RNA.3,4,12-21  More recently, riboswitches, 
mRNA structures that regulate gene expression in bacteria through the use of small 
molecules, have been suggested as a new cellular target for antibacterial drug discovery.10  
Pursuing RNA as a therapeutic target increases not only the number of available targets in a 
cell, but also increases the potential number of small molecules that can be considered RNA 
ligands.  However, our knowledge of RNA recognition by small molecules is still very basic 
and has not progressed as quickly as that of DNA because RNA in solution forms less 
predictable structures. 
 
1.2 RNA Structure 
   RNA exhibits many features similar to those possessed by DNA and/or proteins, 
which makes them attractive from a targeting standpoint.  Its hydrogen bonding capabilities 
allow RNA to fold into complex structures that often provide scaffolding for specific protein 
recognition.  RNA folds so that the short sequences that are complementary form double 
helices to form the maximum thermodynamically stable structure possible.22  The same 
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single stranded RNA sequence can fold to produce many distinct structures, including 
regions of canonical and noncanonical base pairing, bulges, internal loops and hairpin loops, 
and various tertiary interactions (Figure 1.1).  RNA molecules usually contain short double-
helical regions connected by single stranded stretches.  The dominant secondary structural 
element formed when an RNA chain folds back on itself is the hairpin loop or stem-loop 
(Figure 1.1D).22  This structure places complementary sequences spatially close to each 
other to create base pairs that stabilize the overall RNA structure through hydrogen bonding 
and base stacking interactions (Figure 1.1A).  These base paired regions form A-type 
helices, with 11-12 base pairs per turn in a right-handed, anti-parallel double-helix.23   The A-
type helix has a very deep major groove and a shallow minor groove, which unlike the major 
and minor grooves of DNA are less conducive to small molecule binding.24  The major 
groove of RNA contains the discriminatory edges of the nucleobases, while the defining 
feature of the minor groove is the presence of the 2’-hydroxyl groups.25        
Although areas of complementarity can be found in the RNA sequence, there are also 
areas that cannot form canonical pairs.  In addition to the formation of noncanonical base 
pairs, helical stems are often interrupted by bulged bases or bulged loops (Figure 1.1C), 
where bases on one strand have no partner to pair with on the other strand, and by internal 
loops (Figure 1.1B), in which sequences on both strands cannot be paired.22  These 
structures produce defined pockets suitable for binding to other RNAs, proteins,  and small 
metabolites.26  Bulge loops can be either extrahelical or intrahelical, with larger bulges 
causing increased destabilization of the RNA structure.5  One-nucleotide bulges are the most 
common, with single purine bulges tending to stack intralhelically causing the helix to bend, 
while single pyrimidine bulges tend to be extrahelical.27,28  Internal loops have been 
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identified as being important in tertiary interactions,29 and in protein recognition.30  Even if a 
stem-loop contains no interrupted regions in its stem, it must contain a terminal loop, 
sometimes termed a hairpin loop, which links the 5’- to the 3’-strand of its stem.  Terminal 
loops can vary in size, from short sequences that play the same role in RNA as β-turns in 
proteins, to loops that are large enough to contain stem-loops of their own.5,22  RNAs also 
contain tertiary structure, with areas of secondary structure interacting with nucleotides 
distant in the primary sequence.23,31  While advances in the prediction of RNA secondary 
structure have been made,32,33 it is difficult to predict the three-dimensional structure of RNA 
due to its complex and dynamic behavior.5 
Experiments have shown the feasibility of targeting RNA using ligands that recognize 
the above mentioned structural regions in order to modulate gene expression, but there are 
few examples in the literature.34,35  Years of research have resulted in the development of a 
paradigm for small molecule-duplex DNA binding based on the primary sequence of the 
DNA.36  However, research is very far from designing an RNA ligand based only on the 
knowledge of an RNA sequence because, unlike helical DNA, RNA is recognized more by 
its structural features rather than its sequence.1,2,16,26,37-41  Understanding how to enhance or 
prevent RNA-ligand or RNA-protein interactions by blocking their interaction, or by 
disrupting secondary and tertiary structure, will open up new opportunities for drug design.  
In order to target small molecules to RNA, a basic understanding of the overall RNA 
structure is necessary.  Determination of the structure of large RNA molecules through 
crystallographic and nuclear magnetic resonance (NMR) techniques is notoriously difficult.3  
Fortunately, these techniques can be used to characterize the structure of smaller fragments 
of the RNA that contain important structural elements.  Many chemical and enzymatic 
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techniques have also been used to characterize the structural features of RNA.  An important 
advantage of these techniques is that the quantity of RNA required for analysis (nanograms) 
is much smaller than that required (milligrams) for structural studies by NMR and 
crystallography.42  Turning these techniques into a screen for ligands that bind in a specific 
structural region will enhance the ability to identify small molecules that could modulate 
gene expression. 
 
1.3 Chemical and Enzymatic Mapping Techniques for RNA 
 In RNA mapping studies, the RNA of interest is exposed to a reagent and the extent 
of the reaction is quantified at affected nucleotides in the RNA.  The reactivity of the 
nucleotide depends on its structural constraints in solution.  There are two broad classes of 
reagents commonly used for RNA mapping, RNases used in selective enzymatic degradation, 
and reactive small molecules.  Mapping of the entire RNA structure often requires multiple 
reagents be used in parallel.  The choice between using chemical and enzymatic methods for 
probing structural features of RNA depends on what and how information is obtained.  There 
are advantages and disadvantages to both techniques, but their combined use can give 
complimentary information important for determining the overall structure.43    
 1.3.1 Enzymatic Mapping Techniques 
     There are a number of RNases that vary in their specificity for single or double 
stranded regions of RNA, or the sequences recognized.44  In general, enzymatic reactions 
allow more flexibility in the choice of reaction conditions.  The conditions used can be 
similar to physiologically significant conditions unlike those used in chemical mapping.43  In 
practice, sequence and structural information is determined using a number of enzymes, each 
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of which is used to identify a specific nucleotide or structural region.  Reaction conditions 
used maintain the secondary structure of the RNA and allow only single hit kinetics to occur.  
The most commonly used RNases are RNase T1, RNase A, RNase I, and RNase V1.  
Cleavage occurs with RNase T1 at unpaired guanine residues while RNase A cleaves at 
unpaired cytidine and uridine residues.  RNase I cleaves after all four residues equally in 
unpaired regions and RNase V1 shows a preference for paired or stacked nucleotides.  
Dabrowiak and coworkers,45-47 as well as others,48-52 have used RNases to map the binding 
sites of small molecules on RNA.          
1.3.2 Chemical Mapping Techniques 
 Chemical nucleases can be used as a good compliment to the enzymatic nucleases 
commonly used to probe RNA-small molecule interactions.  These nucleases have a specific 
geometry, relatively rigid shapes, and are particularly sensitive to the tertiary structure or 
shape of the RNA binding site.44  They are also smaller in size than protein nucleases, 
allowing them to intimately react with the DNA or RNA substrate.  Chemical modification 
reagents such as dimethyl sulfate and diethyl pyrocarbonate selectively modify base 
positions,53 whereas small molecule reagents such as hydroxyl radicals,45 lead,54 and metal 
complexes,44,55-57 often target the phosphoribose backbone of RNA.56   The following section 
will focus on two metallonucleases, Ru(tpy)(bpy)O2+ and Ru(bpy)32+ (Figure 1.2), that were 
used for chemical mapping in this work.  Both compounds interact with RNA by oxidizing 
the guanine nucleobase.      
1.3.2.1 Nucleic Acid Reactivity to Oxidation 
 Nucleic acids are susceptible to damage in cells by a variety of mechanisms including 
oxidation.  Damage via oxidation can occur either at the sugars through hydrogen 
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abstraction, or at the nucleobases via radical reactions or electron transfer.58,59  Sugar 
oxidation occurs nearly five times slower in RNA than in DNA due to the stabilizing effect 
of the 2’-OH present in the ribose sugar,60,61 and RNA is much more susceptible to hydrolytic 
cleavage of the phosphodiester bond.23,62,63  Base oxidation pathways are similar in both 
DNA and RNA. 
 The reactivity of  the nucleobases toward oxidation is of the order G > A > C ≈ T / U, 
corresponding to the oxidation potentials of the bases.64  Since guanine has the lowest 
oxidation potential, this is where base damage usually occurs in vivo, occurring either 
directly at the guanine position or through migration to a region containing guanine.  
Nucleobase cleavage requires a second chemical step, often alkali treatment, to cause 
complete strand scission.59  In DNA, this alkali treatment causes hydrolysis of the glycosidic 
bond, leaving an abasic site, which can undergo β-elimination of the 3’ phosphate.59  In 
RNA, all phosphodiester linkages are subject to alkaline hydrolysis due to the presence of the 
2’-hydroxyl.  Hydrolysis of the phosphodiester linkages occurs faster in RNA than the 
creation of an abasic site and β-elimination.59  In practice, aniline is used to facilitate 
complete strand scission in RNA, while piperidine is used for DNA.   
 One electron oxidation of RNA bases leads to the production of a guanine radical 
cation59 that is a relatively strong acid (pKa = 3.9).65  In the mechanism of oxidation 
determined in DNA (Figure 1.3), the guanine radical undergoes rapid deprotonation to 
generate the neutral radical.  This is then followed by O2 addition and the eventual 
production of the products imidazolone and oxazolone.  Alternatively, the guanine radical 
cation can become hydrated followed by one electron oxidation to form 8-oxo-guanine.59  8-
oxo-guanine is the only product detected in vivo and has become an important marker for 
 8 
DNA damage.66  The preferential degradation pathway of the guanine radical cation 
(hydration vs. deprotonation) depends on the context of the guanine.  Nucleosides and single-
strands of nucleic acid are expected to favor the imidazolone and oxazolone pathway, 
whereas base paired guanines are expected to favor the 8-oxo-guanine pathway due to 
stabilization of the radical cation.59       
1.3.2.2 Metallonucleases as RNA Mapping Reagents  
The ability for metallonucleases to interact with DNA and cause chemical 
modification has been known for some time, and their mechanism of action and resulting 
cleavage products have been studied in great detail.57,59,61,67  Many of these same compounds 
have also been used to map the structure of RNA, although the mechanism has not been 
studied as in depth, and has in many cases been assumed to occur in the same manner as that 
of DNA.  Some metallonucleases are able to interact directly with the nucleobase due to their 
high oxidation states that are generated either chemically or electrochemically, while other 
cleavage agents are activated photochemically.  An appealing characteristic of photochemical 
reagents is that all the components of a system to be studied can be mixed together without 
initiating the chemical reaction until the sample is irradiated.67  Provided that the 
chromophore of the photocleavage agent is sensitive to light greater than 300 nm in 
wavelength, select excitation of the cleavage agent will occur.   The ability to “tune” the 
nuclease by changing the ligands allows complexes to be synthesized to match the desired 
nucleic acid target.  Various metal ligands can be added to the metallonuclease to change 
their photophysical, photochemical, and redox properties (Figure 1.4).  These can be 
intercalating ligands such as dipyridophenazine,68 electrostatic or solvent bound ligands such 
as bipyridine,69 or groove binders such as phenanthroline.57  Thorp and coworkers,42,70-72 
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among others,57,73-76 have explored many DNA and RNA structures using transition metal 
oxidation chemistry.  The following discussion focuses on two metallonucleases, 
Ru(tpy)(bpy)O2+ (RuO2+, bpy = 2,2’-bipyridine, tpy = 2,2’,2’’-terpyridine) and Ru(bpy)32+, 
and their use as probes of RNA structure.     
1.3.2.3 Ru(tpy)(bpy)O2+ as an RNA Chemical Mapping Agent and Screen for Small 
Molecule Binding  
 Meyer and coworkers first reported the synthesis of Ru(tpy)(bpy)O2+ in 198177 and 
later reported that the complex could oxidize organic hydrocarbons and alcohols.78,79  The 
complex is made as the aqua complex and is converted via bulk electrolysis to the oxidized 
oxo complex through a coupled two proton, two electron process.  Since the discovery that 
RuO2+ could oxidize DNA under anaerobic conditions,80 RuO2+-nucleic acid oxidation 
chemistry has been studied extensively.81-85  Due to its size (6 Ǻ)  and charge (2+), the RuO2+ 
compound shows preferential binding to solvent accessible guanines that are prone to cation 
binding.42,81,86  It is postulated that oxidation occurs through an inner-sphere Ru(III)-O-G 
intermediate.  Hairpin structures such as the transactivation response (TAR) RNA sequence, 
tRNAPhe, and the iron responsive element (IRE) sequence found in human and bullfrog 
ferritin have been oxidized with RuO2+, and show the greatest extent of damage at loop 
guanines (Figures 1.5 and 1.6).55,81,87     
 tRNAPhe (Figure 1.6) was studied using RuO2+ chemistry due to the available X-ray 
crystal structure and the ability to control the RNA conformation via salt concentration.55  In 
the folded state, tRNAPhe was cleaved mainly at guanines and adenines in the D- and 
anticodon loops.55  Guanines in the TAR RNA sequence from HIV-1 (Figure 1.5C) were 
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also studied using RuO2+ chemistry,55 and it was observed that guanine nucleobases found in 
the loop (G17, G18, and G19) were oxidized more efficiently than guanines found in the stem.   
The iron responsive element has also been studied using RuO2+ oxidation 
chemistry.42,81,88  In the first study,42 the IRE in full-length bullfrog ferritin mRNA (Figure 
1.5A) was probed with RuO2+.  Cleavage was seen only at position G16 (the IRE has been 
renumbered since the original publication, and was originally termed G14), and not at any 
other unpaired guanine residues indicating that this residue was highly solvent exposed.  It 
was concluded that guanine residues other than G16 were spatially inaccessible to the reagent.  
Lack of cleavage at other unpaired guanine residues was later explained by NMR structural 
data that suggested that the guanines predicted to be unpaired in the secondary structure were 
involved in tertiary interactions with other parts of the RNA molecule.89  Further studies 
confirmed that the G16 residue is flipped out of the RNA structure and is solvent exposed, 
allowing it to make important contacts with the iron regulatory protein (IRP).  Ciftan et al. 
studied oligonucleotides corresponding to the 30 base IRE hairpin structure and 55 base IRE 
hairpin with flanking region.81  RuO2+ cleavage revealed more cleavage sites than in the 
previous study although G16 was still oxidized to the greatest extent.  Other unpaired guanine 
residues were also oxidized, which was consistent with the expectations from the predicted 
secondary structure.   
Tibodeau used RuO2+ oxidation chemistry to map the human ferritin IRE RNA 
structure (Figure 1.5B), and further explored the use of RuO2+ to screen for small molecules 
that interact with IRE RNA.88,90  The development of RuO2+ chemistry into a footprinting 
technique would be a useful screen for identifying functional small molecule-RNA 
interactions.  The ability of thirteen small molecules to interact with a specific binding pocket 
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in the IRE RNA was probed using RuO2+.  Three molecules that bound to this pocket were 
identified, and the effect of one small molecule, yohimbine, on ferritin gene expression was 
examined.  This small molecule was able to up-regulate ferritin protein synthesis in vitro, 
validating the use of RuO2+ as a small molecule screen.   
1.3.2.4 Ru(bpy)32+ as a Chemical Mapping Agent: The Flash-Quench Technique 
 Photolysis of a ruthenium chemical mediator to cause oxidative damage in DNA has 
been studied extensively by Barton and coworkers.91,92  This oxidative damage occurs 
primarily through base-labile guanine oxidation.  The metal complexes have been used to 
study events such as mismatch recognition93,94 and electron transfer from peptides to 
DNA.95,96  Transition metal complexes such as ruthenium and rhodium can act as direct 
photooxidizers in the flash-quench experiment,91 the reaction scheme for which is shown in 
Figure 1.7.   The flash-quench cycle is first initiated by visible light which excites the Ru2+ 
complex.  The excited ruthenium(II) complex *Ru2+ is then quenched by a nonintercalating 
electron acceptor (Q), to form Ru3+.  The Ru(III) species can be reduced back to the Ru(II) 
form either through recombination with the reduced quencher (Q-), or through electron 
transfer with a nearby guanine base resulting in an oxidized guanine radical.  The oxidized 
guanine radical can return to the resting state by reaction with the reduced quencher or 
undergo further reaction to form the guanine oxidation products shown in Figure 1.3.  The 
flash-quench technique was first used to characterize electron transport in proteins,97 and was 
later modified for DNA oxidation.91  Recently, Dana Holcomb in our lab has adapted this 
technique for its use in the oxidation of RNA. (unpublished results)     
 This flash-quench reaction for oxidation of guanine nucleobases in RNA uses the 
Ru(bpy)32+ complex as the photooxidizer and Co(NH3)5Cl2+ as the quencher.  Ru(bpy)32+ is a 
 12 
common example of an external RNA binder, and its binding is governed by both solvent 
binding and electrostatic contributions.74,98  The electron transfer between guanine and 
Ru(bpy)33+ occurs in less than 200 ns, and once formed, nearly all the guanine radicals decay 
within 100 µs.91,92,95  The irreversible reaction of the guanine radical with either oxygen or 
water yields oxidative lesions that can be analyzed by gel electrophoresis.95  The flash 
quench-method of RNA mapping showed oxidation of the guanine residues in the human 
ferritin IRE in a similar pattern to those identified using the RuO2+ compound.  Preferential 
oxidation was seen at those residues which were readily solvent accessible and not residues 
whose flexibility allowed them to become solvent exposed over time.  The use of Ru(bpy)32+ 
as a footprinting technique continues to be examined in this work.                                
 
1.4 Molecular RNA Targets 
 Promising results have been obtained using a number of small molecules to target 
RNA, offering a complimentary approach to the targeting of proteins.  Small molecule 
ligands have been identified with three major classes of RNA targets in mind: antibacterial, 
antiviral, and mRNA.  Within each of these classes, various avenues have been pursued to 
achieve gene expression regulation, including inhibiting RNA-protein interactions and 
preventing protein production by binding to a functionally relevant RNA.  To date, all 
clinically approved RNA-targeting drugs exert their effect by binding to ribosomal RNA.26 
1.4.1 Antiviral Targets: Transactivation Response RNA (TAR RNA)         
 Once it was determined that small molecules could regulate gene expression both in 
vitro and in vivo, work progressed on endogenous RNA targets.  RNAs with highly 
structured regions were identified, with a focus on those structured regions involved in an 
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RNA-protein complex.  One example of this interaction is between the TAR RNA and the 
Tat protein involved in the regulation of HIV-1.   
The HIV-1 genome is made up of a ~9 kb genomic RNA encoding for 15 proteins.99  
After integration into the host cell genome, the initial phase of the viral life cycle begins with 
transcription from the 5’ end of the RNA.  Although transcription is critical to viral 
proliferation, RNA polymerase II transcribes poorly from the viral promoters.  The HIV-1 
protein Tat helps facilitate efficient transcription of the viral genome.  In the presence of the 
Tat protein, the rate of transcription increases nearly 100-fold to produce full length genomic 
RNA.99  Inhibition of the Tat-TAR interaction by binding to TAR, in order to slow or halt 
production of the viral transcript, has been sought as a potential anti-HIV strategy.100,101  Tat 
has been shown to bind to a specific bulged region in the TAR RNA hairpin loop at the 
beginning of the viral transcripts.102,103           
A variety of techniques have been used to identify compounds able to inhibit the Tat-
TAR interaction, including gel mobility shift assays, absorption and fluorescence 
spectroscopy, mass spectrometry, footprinting experiments, scintillation proximity assays, 
NMR, and computational screening.52,104-107  Initially, a collection of aminoglycosides was 
screened for their ability to disrupt the Tat-TAR interactions.108  Neomycin was found to be 
the most potent aminoglycoside with an IC50 of 0.92 µM.  In subsequent experiments it was 
demonstrated that the binding site for neomycin was located below the bulged region in TAR 
RNA.  It has been suggested that binding of neomycin induces a conformational change in 
the TAR RNA, increasing the off-rate of the Tat-TAR complex.109  Later, Mei and coworkers 
developed a high-throughput in vitro screening method and were able to screen 
approximately 150,000 compounds for their ability to interrupt the Tat-TAR interaction.107  
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From this screen, two promising compounds were identified, quinoxaline and 
tetraaminoquinozaline.  The James group has used computer-aided drug design to identify 
compounds that are candidates for blocking the Tat-TAR interaction.101,110  Acetopromazine 
was identified through the use of a docking program and was found to completely inhibit 
formation of the Tat-TAR complex at a concentration of 100 nM.101  An NMR structure was 
obtained, showing that acetopromazine bound to TAR RNA in an area containing a 
trinucleotide bulge.110  It was later shown that acetopromazine was able to bind internal 
bulges and terminal loops, but not double stranded RNA or tetraloops.111  
1.4.2 mRNA Targets: Inhibiting Ribosome Scanning 
Translation in eukaryotes proceeds first with the binding of the small ribosomal 
subunit to the eIF-2·GTP·Met·tRNAi complex, followed by binding to the 5’ cap of 
mRNA.112  The 5’ end of the mRNA molecule is recognized by the presence of its 5’ cap and 
two bound initiation factors, eIF4e and eIF4G.  The small ribosomal subunit complex then 
begins scanning the transcript, searching the 5’UTR for the first AUG codon.  After 
recognition of the codon by Met-tRNAi, the complex pauses and waits for the large 
ribosomal subunit to associate before translation begins.  Secondary structure in the 5’UTR is 
known to pause or inhibit the scanning process, resulting in translation inhibition.  By 
binding of a small molecule within the 5’UTR of a specific mRNA, inhibition of translation 
and modulation of gene expression can occur.     
The in vitro selection process known as SELEX (systematic evolution of ligands by 
exponential enrichment) has been used to identify ligands that are able to regulate gene 
expression in vivo.4,34,113  Werstruck and Green34 have identified an aptamer for Hoechst dye 
33258, which when inserted in to the 5’UTR of a mammalian β-glactosidase mRNA, 
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decreases the in vivo expression of β-galactosidase activity by greater than 90 %.  Internal 
controls determined that the effects of Hoescht 33258 were not due to general translation 
inhibition.  In the same manner, Grate and Wilson113 have placed an aptamer to malachite 
green in the 5’UTR of the CLB2 gene, which encodes for a cyclin that directs the cell cycle 
transition from G2 to mitosis in budding S. cerevisiae.  They have shown that ligand-induced 
folding of the 5’UTR limits binding by the 40S ribosomal subunit and results in a reduction 
in the rate of translational initiation.   
 
1.5 Principles of RNA Binding       
Recent work has focused on determining the biochemical and biophysical rules 
governing small molecule-RNA binding.16,21,107,114  Compounds that interact with RNA show 
marked differences from those typically identified as being “drug like” by Lipinski’s rules 
and can make targeting a specific RNA difficult.1,14-16,21,115  The small molecules often 
exceed the established molecular weight limits and are more hydrophobic or polar in nature 
than common drugs, due to the need to interact with the negatively charged RNA.  Both of 
these features could cause a reduction in the bioavailability of the compound.  Most small 
molecules also have only modest selectivity and affinity for their RNA target when compared 
to their protein counterparts.26  The binding constants for many RNA-small molecule 
interactions are relatively weak, falling in the low micromolar range.14  These drugs can 
however be sufficiently potent if binding causes or inhibits a conformational change in the 
RNA.   
The general affinity of the aminoglycosides for many different RNAs leads to their 
often being the first compounds investigated for binding to a new RNA target.   Due to their 
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promiscuity, the compounds are often useful for in vitro studies, but less useful for cell 
culture or in vivo work.26  Aminoglycosides can also be very toxic at high concentrations.  
Still, a large amount of data has been collected on the aminoglycoside-RNA interaction, and 
certain basic principles have emerged that will aid in designing future RNA ligands.  
Aminoglycosides have been found to bind pockets created by bases in and around internal 
loops and bulged regions or those created by noncanonical interactions.  They have shown a 
strong dependence for electrostatic interactions, as well as nonionic interactions.  They also 
have shown that shape complementarity (how well the ligand and RNA fit together) as well 
as conformational adaptation (binding induced changes in the ligand and RNA) are a major 
contributor of the specificity of small molecules for RNA.     
Using the knowledge of binding principles provided by the aminoglycosides, the 
Hergenrother group have shown that subsets of deoxystreptamine dimers are able to 
selectively bind RNA tetraloops and octaloops through the use of a combinatorial library of 
105 deoxystreptamine dimers.1,39  Ligand binding was assessed using fluorescein labeled 
RNA to obtain an estimate of the dissociation constant and the ligand binding site was 
determined using RNase footprinting.  Two compounds with nanomolar affinity for hairpin 
loops were identified using this screen, one showing preferential binding to a tetraloop, and 
the other to an octaloop.  These were the first compounds reported to show discrimination 
between RNA hairpin loops of various sizes.  More work needs to be done to identify the 
RNA motifs that small molecules prefer so that compounds can be efficiently designed.  In 
this same area, understanding the characteristics of the small molecules that increase their 
effectiveness on gene expression modulation is important.     
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The rational discovery of small molecule ligands for RNA is still in its infancy 
compared to the use of these small molecules to bind proteins and DNA.  The complex 
structure of RNA increases the difficulty in the identification of potential ligands.  To date, 
the small molecules identified have little in common as far as their structures and modes of 
interaction, making it is hard to generalize what qualifies as a good RNA binder.  Detailed 
characterization of small-molecule RNA interactions, along with methods for high 
throughput screening are necessary to progress toward the goal of selectively targeting RNA 
with small molecules.            
 
1.6 Dissertation Focus 
 This dissertation focuses on the use of secondary structures in mRNA as a small 
molecule drug target for regulation of gene expression.  Two model systems are investigated, 
the iron responsive element in the human ferritin mRNA, which is studied in Chapter 2, and 
the preproinsulin glucose regulatory element found in the human preproinsulin mRNA 
studied in Chapter 3.  Chapter 2 focuses on the ability of a compound identified using 
oxidation chemistry to regulate ferritin gene expression.  In Chapter 3 the secondary structure 
of the preproinsulin glucose regulatory element is first mapped with transition metal 
complexes and RNases, then the mapping agents are used to screen for small molecules that 
bind to the preproinsulin mRNA.  The effect of these compounds on gene regulation is 
further studied using an in vitro cell-free expression system.     
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1.7 Figures  
 
Figure 1.1. Schematic representation of four general classes of RNA secondary structure. A) 
Base paired RNA forming a helix or duplex structure.  B) In an internal loop secondary 
structure, sequences on both strands cannot be paired.  C) A bulged region in RNA occurs 
when bases on one strand have no partner on the other strand to base pair with.  D) Hairpin 
loop, or stem loop region consisting of a base paired “stem” region with an unpaired terminal 
loop.  The bold line represents a canonical base pair, whereas the circle represents a 
noncanonical G-U wobble pair.         
  
A 
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Bulge Hairpin Loop 
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Figure 1.2.  Structures of the two metal complexes used as metallonucleases in this work 
 
 
 
 
Ru(tpy)(bpy)O2+ 
Ru(bpy)32+ 
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Figure 1.3. Proposed mechanism of guanine oxidation in DNA (adapted from Burrows59).  
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Imidazolone Oxazolone 
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Figure 1.4. Common aromatic ligands used to change the binding properties of 
metallonucleases.  Bipyridine (bpy) ligands (A) are an example of an electrostatic ligand and 
also known as external binders.  3,4,7,8-tetramethylphenanthroline (B) and phenanthroline 
(C) are known groove binders in DNA.  9,10-phenanthrenequinone diimine (D), 
dipyridophenazine (E), and 4,7-diphenyl-1,10-phenanthroline (F) are known intercalators.            
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Figure 1.5.  Schematic representations of the secondary structure of RNAs mapped with 
metallonucleases.  A) Proposed bullfrog ferritin IRE secondary structure.89  Bold residues 
represent bases that make direct contacts with the IRP protein.116  B) Proposed structure of 
the human ferritin IRE.88  There is a base pair across the hairpin loop between C14 and G18.  
C) Proposed secondary structure of the TAR element found in HIV-1.101  Bold residues 
represent bases critical for binding of the Tat protein.    
A B C 
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Figure 1.6.  Proposed secondary structure of tRNAPhe.117  Most guanine oxidation occurs in 
the D- and anticodon loops.   
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Figure 1.7.  Flash-quench reaction scheme and structures of Ru(bpy)32+ and Co(NH3)5Cl2+.  
In this scheme, G = Guanine, Q = Quencher.  Visible light excites the Ru(bpy)32+ species to 
form *Ru(bpy)32+.  This excited complex is then quenched by the nonintercalating 
Co(NH3)5Cl2+ electron acceptor to form Ru(bpy)33+. The Ru(bpy)33+ can then be reduced 
back to Ru(bpy)32+ either through recombination with the reduced quencher or through 
electron transfer with a nearby guanine base resulting in a guanine radical.  The guanine 
radical can return to its resting state by reacting with the reduced quencher, or can undergo 
further reaction to form 8-oxo-guanine or one of its reaction products.      
Q = Co(NH3)5Cl2+ Ru = Ru(bpy)32+ 
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Chapter 2 
 
In Vitro Up-regulation of Ferritin Protein Synthesis by Small Molecules 
that Target the Iron Responsive Element in Ferritin mRNA 
 
2.1 Abstract 
 RNA is an attractive therapeutic target because of its many functions in the cell and 
its lack of a cellular repair mechanism.  Previous work with a Ru(tpy)(bpy)O2+ (RuO2+, bpy 
= 2,2’-bipyridine, tpy = 2,2’,2’’-terpeyridine) screen has identified four small molecules that 
are able to specifically and selectively bind to the iron responsive element (IRE) structure in  
human ferritin mRNA.  One small molecule, promazine, has been identified that binds to an 
internal bulge region in the IRE sequence that makes important contacts with the iron 
regulatory protein (IRP).  An RNase I footprinting assay has confirmed that promazine binds 
in the bulge region of the IRE.  Using an Electrophoretic Mobility Shift Assay (EMSA), we 
have shown that this compound can disrupt the binding of IRP1 and IRP2 to the IRE 
sequence.  Finally, binding of promazine significantly increases the production of ferritin in 
an in vitro translation system, and is also able to up-regulate synthesis of the luciferase 
protein from an engineered IRE-luciferase gene.       
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2.2 Introduction 
2.2.1 Cellular Iron Homeostasis 
Iron (Fe) is both an essential nutrient and a potential toxin that plays a role in the 
metabolism of all cells.1  It is critical to many diverse functions of the cell, such as DNA 
replication, electron transfer, and oxidative stress control.  Paradoxically, the presence of 
high levels of iron can be harmful, causing inflammation, tissue damage, and toxicity.  At 
physiological pH, ferric iron (Fe3+) is extremely insoluble and its ability to react with oxygen 
to produce dangerous free radicals leads to extremely low free iron concentrations in the cell, 
with much of the Fe3+ complexed with proteins.2  It is the balance between the beneficial 
aspects of cellular iron and its toxicity that is a challenge.  This leads to tight regulation of 
the acquisition, storage and utilization of cellular iron. 
 An intricate system has been developed to handle the iron needs of mammalian cells.  
This system involves iron transport and storage proteins (transferrin and ferritin, 
respectively), RNA-binding proteins (iron regulatory proteins 1 and 2; IRPs) that regulate the 
transport and storage proteins, and specific RNA sequences/structures (iron responsive 
elements; IREs) that are the recognition sites for the RNA-binding proteins.  Much work has 
been done by Theil,3-6 Munro,7-9 Rouault,10-12 Leibold,13,14 and others to elucidate the details 
and mechanisms of this system.  While there are still some unanswered questions, this system 
is one of the most well understood regulatory systems to date. 
2.2.1.1 Iron Absorption and Transport 
The human body contains ~3-5 g iron, with only 0.5-2 mg entering and leaving the 
body daily.15  The vast majority of iron in the body is used in erythroid cells for heme and 
hemoglobin synthesis.  In mammals, non-heme iron (Fe3+) is absorbed from food by 
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enterocytes in the duodenum.  The ferric iron is first reduced by a ferric reductase to Fe2+ and 
is transported into the enterocyte by the transmembrane iron transporter DMT1 (divalent 
metal transporter 1).  Once inside, excess iron is either stored in ferritin, or is exported 
outside the cell through the basolateral membrane to reach plasma by an iron exporter, 
ferroportin1.  The Fe2+ is then oxidized to Fe3+ by a ferroxidase, likely either the plasma 
ferroxidase ceruloplasmin, or its membrane associated analogue hephaestin.15-18  Ferric iron 
is then loaded into apo-transferrin to give holo-transferrin, although the mechanism by which 
this occurs is not yet understood.  In this form the insoluble Fe3+ can circulate throughout the 
body in the plasma and is no longer toxic.   
2.2.1.2 Cellular Iron Uptake: Transferrin-mediated Endocytosis 
There are four cell types that have special functions in iron handling; the duodenal 
enterocytes that function to absorb iron from food sources, erythroid precursors which 
incorporate all the iron they uptake into hemoglobin, hepatocytes which store the iron not 
needed elsewhere, and the recticuloendothelial macrophages which carry out iron recycling 
and also store iron.15  Each of these cell types handles iron in a different way.  A number of 
mechanisms have evolved for the uptake of iron, but the major method is the transferrin-
mediated endocytosis pathway (Figure 2.1).18   
The transferrin protein (Tf) has a molecular mass of approximately 80 kDa and binds 
tightly to the Fe3+ ions with an approximate Kapparent of 10-20 M-1, making the iron difficult to 
extract forcing the entire complex to be brought into the cell before iron is released.19  Holo-
transferrin binds the transferrin receptors (TfR1 and TfR2; generally TfR) at the cell surface.  
The TfR/Tf complexes localize to clathrin-coated pits, which are endocytosed and form a 
specialized endosome.  After the loss of the clathrin coat, the endosomes are acidified to pH 
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5.5 through the use of a proton pump.  This leads to conformational changes of the transferrin 
protein and release of the iron.  The apo-transferrin and TfR are recycled to the cell surface 
where they dissociate at neutral pH and can be used in further cycles of iron binding and 
uptake.  Subsequently, the released Fe3+ is reduced to Fe2+ inside the endosome and is 
transported by DMT1 into the cytoplasm where it is either utilized by the cell or stored.     
2.2.1.3 Cellular Iron Storage: Ferritin   
 The portion of iron taken into the cell that is not needed for immediate use is stored as 
a reserve in case body iron levels become low.  Because free iron would aggregate and form 
toxic precipitates, the iron is stored in the protein ferritin.  Ferritin (480 kDa) is a ubiquitous, 
highly conserved binding protein that can store up to 4500 iron atoms in its hydrated ferric 
oxide core.15,17,19  In mammals, ferritin is a heteropolymer made up of 24 subunits of two 
types, heavy (H-, 21kDa) and light (L-,19 kDa), which are encoded by their corresponding 
genes.1  The ratio of H to L subunits is dependent on the tissue in which the ferritin is 
expressed.  The H subunit contains inherent ferroxidase activity, converting Fe2+ found in the 
cytosol to Fe3+ as the iron is internalized into the mineral core.15,18,20  The L subunit has been 
shown to be play a role in the formation of the iron core.20  Degradation of ferritin resulting 
in iron release helps to mobilize iron for utilization by the cell.  Although little is known 
about the degradation mechanism, lysosomal and proteosomal pathways have been 
implicated.17  The importance of ferritin is demonstrated by the fact that ferritin H gene 
deletions are lethal in mice20 and mutations in the gene encoding the L subunit causes defects 
in the central nervous system in mice.21  
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2.2.2 Regulation of Cellular Iron Homeostasis: Regulation of Transferrin and Ferritin by 
Iron Regulatory Proteins (IRPs) and Iron Responsive Elements (IREs) 
 Together ferritin and transferrin regulate the concentration of cellular iron.  They are 
under tight genetic control and their expression can be up- or down-regulated depending on 
iron availability.  When presented with iron overload, transferrin receptor synthesis is down-
regulated to stop iron uptake, and ferritin synthesis is increased to sequester excess iron.  In 
times of iron deficiency, a higher number of TfRs are presented at the cell surface to increase 
the amount of internalized iron, and synthesis of the ferritin storage protein is stopped 
thereby increasing iron availability.22  The balance between ferritin and transferrin synthesis 
is achieved by regulatory mechanisms that include modulating transcription, mRNA stability, 
translation, and post-translational modification.  Post-transcriptional regulation is currently 
the best characterized.17  This system includes trans-acting iron regulatory proteins (IRPs) 
interacting with iron responsive elements (IREs), conserved secondary structures found in 
untranslated regions of the mRNA.         
       There are two known IRPs, IRP1 and IRP2.  Both proteins are universally 
expressed and have evolved to sense cellular iron concentration and modify gene expression 
accordingly.  IRP1 is involved in basal mammalian iron homeostasis, while IRP2 is the 
predominant post-transcriptional regulator of iron metabolism in response to the level of iron 
in the cell.23  Human IRP1 is reported to share 57-61% sequence identity and 75-79% 
similarity with human IRP2.1,16  Each protein is made up of four domains with domains 1-3 
connected to the fourth domain by a flexible hinge region.24  This arrangement creates an 
active site cleft between the three compact domains and the fourth.  Mutagenesis25 and 
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footprinting26 of the IRE-IRP1 interaction have shown that residues close to the entrance of 
the active site are important in IRE binding.                
IRP1 (previously called translation regulator protein P-90,27  iron-responsive element-
binding protein 1,14,28 iron regulatory factor,29,30 or ferritin repressor protein31) is a 98 kDa 
protein coded in human chromosome 9 and has been more thoroughly characterized than 
IRP2.  It is a bifunctional protein, which can act as a functional cytosolic aconitase, 
converting citrate to isocitrate, or an RNA-binding protein.  A recent crystal structure of 
IRP1 reveals that the structure is very similar to that of the mitochondrial aconitase.24  The 
modulation between the aconitase form and the RNA-binding form of IRP1 depends on the 
presence of an iron-sulfur [4Fe-4S] cluster that blocks RNA binding.16,32  The iron-sulfur 
cluster is coordinated in the active site by three cystines, leaving the fourth residue to bind 
solvent and substrate.22,33  When the iron-sulfur cluster is bound in the active site, IRP1 
looses the ability to bind to RNA.  In iron deficient cells or those under oxidative stress, the 
cluster disassembles and apo-IRP1 gains RNA binding activity.34,35  This RNA binding 
activity can act to either stabilize TfR mRNA, or repress ferritin synthesis in cells.36-38  IRP1 
also responds to other stimuli.  Exposure of cells to hydrogen peroxide (H2O2) or nitric oxide 
(NO) promotes removal of the [4Fe-4S] cluster and induces IRE-binding activity.22,34,35,39      
The active site for RNA binding has been shown to overlap that of the aconitase 
active site.32  The crystal structure of IRP1 holo-protein shows a closed conformation 
(domain 4 closing onto domains 1-3) that does not allow access of substrates to the active 
site.24  The IRE has a shape similar to the portion of domain 4 that interacts with domains 1-3 
leading to the hypothesis that the IRE binding is able to substitute for domain 4 binding, 
resulting in a widened cleft region.1,33  A more detailed characterization of the IRE binding 
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site in IRP1 has become available with the crystallization of IRP1:ferritin H-chain IRE 
RNA.37,38  This work has also lead to a greater understanding of the RNA-protein contacts 
that are made between IRE RNA and IRP1.   
IRP2 is a 104 kDa protein that is highly homologous to IRP1 but lacks aconitase 
activity most likely due to its inability to assemble an [4Fe-4S] cluster.  IRP2 is distinguished 
from IRP1 by a 73 amino acid segment that is responsible for functioning as an iron sensor 
and mediating proteolytic cleavage of the protein in iron replete cells, though the details of 
this mechanism are not yet known.1,16,33  In the presence of iron, proteosomes bind to the 
IRP2 protein and degrade it, preventing its interaction with IREs. Mice that lack IRP2 
develop anemia due to insufficient erythroid expression of TfR and overexpression of ferritin 
that depletes cells of iron needed for heme synthesis.40  IRP2 -/- mice exhibit a 200-fold 
increase in synthesis of the porphyrin heme precursor protoporphyrin IX than wild-type 
mice;41 in adulthood these mice develop progressive neurodegenerative disease.40  IRP2 has 
been shown to dominate regulation of iron homeostasis and can compensate for the loss of 
IRP1.23  
IRP1 and IRP2, in their RNA binding forms, have been extensively studied.14,42,43  
The interaction between the protein and RNA is very strong with the dissociation constant 
between IRP1 and the wild-type ferritin IRE being between 10 and 90 pM.7,10  Both IRPs 
bind with equally high affinity and specificity to a consensus IRE sequence, although each 
IRP binds a different subset of IRE-like sequences.42,44 
A number of genes that code for proteins involved in iron homeostasis contain a non-
coding sequence of 28-30 nucleotides called the iron responsive element (IRE).45-47   IREs 
are highly conserved stem loop RNA structures that act as IRP binding sites. There are 
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several aspects of IRE secondary structure that are important for high-affinity binding to the 
IRPs.7  The consensus IRE sequence contains a conserved 6-nt loop with the sequence 5’-
C14A15G16U17G18N -3’ where N can be A, C, or U (Figure 2.2).  The hexaloop contains a 
C14-G18 base pair across the loop which helps stabilize the loop structure, whereas G16 is 
flipped out and solvent exposed.  This structure is supported by both NMR48-50 and chemical 
cleavage studies.6,51,52  In vitro evolution experiments have shown that the highest affinity 
loop structure for the IRP proteins is one where there is a hydrogen bond between the 14 and 
18 positions, allowing for nucleotides 15-17 to be accessible for protein binding.44  
Additionally, mutational analysis has shown that nucleotide substitutions at either the C14, 
G18 position, or at the C8 bulge of the stem, decreases IRP1 binding 36-99% depending on 
the specific mutation.44   
 This loop region is flanked by an upper and lower stem region separated by a small 
bulged region containing an unpaired cytosine on the 5’ side.  The upper stem region is a 5-
bp long helix with variable sequence, and the lower base paired region does not contain 
sequence or length constraints.53  Point mutations that disrupt the upper stem helix were 
found to be non-functional whereas mutations that did not disrupt the double stranded nature 
of the stem were functional.7,9,54   Fully functional IREs are likely to have longer lower stems 
either to allow more extensive interactions of the RNA with the IRPs or to stabilize the 
conformation of the stem-loop.11,46  It has also been indicated that the stem region is 
predicted to be a potential target for small molecule drugs, allowing discrimination and 
selectivity between sequences.55  IRE conservation for the same gene between different 
species is >95% while conservation between different genes in the same species is only 36-
55%.47  The ferritin IRE has an internal loop in the stem region made up of U6, G7, C8, and 
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C25, where G7-C25 are base paired and U6 and C8 remain unpaired.  In contrast, the transferrin 
IRE has only one unpaired base in the stem, C8.   
 The ferritin mRNA contains one copy of the IRE sequence in its 5’ untranslated region 
(UTR) that is used to regulate ferritin synthesis.  The position of the IRE relative to the 
location of the 5’ UTR cap structure of the mRNA is important, with locations >60 nt from 
the cap leading to a reduction of translational control.56  In cases of low cellular iron levels, 
the IRP binds to the IRE preventing ferritin protein synthesis, and preventing the storage of 
iron needed elsewhere.  Binding of the IRE by the IRP prevents the recruitment or scanning 
of the 40S ribosomal subunit to the ferritin mRNA interfering with translational initiation.57  
In times of a high cellular iron level, the IRP is unable to bind to the IRE allowing ferritin 
protein synthesis to occur (Figure 2.3).  This type of post-transcriptional regulation is also 
present for mammalian mitochondrial aconitase,58,59 erythroid amino levulinic acid 
synthase,60 (eALAS) which catalyzes the first step in heme synthesis, and the iron exporter 
ferroportin 1.18  There is also evidence of an IRE-like structure in the 5’ UTR of the 
Alzheimer’s amyloid precursor protein transcript.61       
 The transferrin receptor is regulated in a slightly different fashion, although still by IREs.  
Five copies of the IRE are found in the 3’ UTR region of the transferrin receptor transcript 
and mediate mRNA stability thereby regulating receptor levels in the cell (Figure 2.4).43,62,63  
In iron deficient cells, translation of the transferrin receptor is up-regulated to increase the 
amount of iron brought into the cell.  This occurs by the binding of IRPs to the IRE in the 
3’UTR, which protects the transcript from endonucleolytic cleavage and degradation by 
blocking the cleavage sites.47  In cases of high cellular iron, transferrin receptor synthesis is 
shut off by the inability of the IRPs to bind to the IRE, either through proteosomal cleavage 
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of IRP2 or iron-sulfur cluster formation in IRP1.  This reduces the number of TfRs at the 
surface of the cell resulting in a decrease in the amount of iron brought into the cell.  
Regulation of DMT1, a divalent metal transporter involved in iron homeostasis also occurs 
via the mediation of mRNA stability through an IRE located in the 3’ UTR of its transcript.17   
 The binding of IRP1 to the ferritin IRE has been extensively studied.37,38,51  Footprinting 
reactions, using both chemical and enzymatic nucleases, were performed on the consensus 
IRE (28-mer) as well as a 55-nt sequence containing the IRE and flanking regions.27  The 
IRP1 binding site was found to completely cover the IRE and this interaction resulted in an 
increase in the helical nature of the stem as shown by increased sensitivity to RNase 
V1.27,28,54  Mutagenesis of the IRE consensus sequence has revealed that disrupting the base 
pairing of the stem structure reduces protein binding 400-500 fold.9  Also, replacing G18 in 
the hexaloop by an A, or deletion of C8 in the internal bulge, completely shut off protein 
binding.3  More recently, a crystal structure of the rabbit Cys437Ser/Cys503Ser double-mutant 
IRP1 in complex with the bullfrog ferritin H IRE was solved, and has led to a more detailed 
understanding of the specific contacts made between the IRP1 protein and the IRE RNA.37,38   
2.2.3 Identification of Small Molecules that Disrupt the IRP:IRE Interaction 
 Previous work has shown that chemical and enzymatic footprinting techniques are 
able to identify the precise binding site of small molecules on an RNA target.55,64-68  In the 
body only about half of the available ferritin mRNA is activated.43  A strategy for increasing 
the pool of available ferritin is to block the binding of the IRP protein to the IRE RNA with a 
small molecule.  The challenge is to selectively target the ferritin IRE isoform as opposed to 
the IRE isoforms found in other proteins involved in iron homeostasis such as the transferrin 
receptor.  When compared with other IRE sequences the human ferritin IRE contains a 
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unique internal bulged region created by the unpaired U6 and C8 residues.50,69-71  Specific 
RNA:protein contacts are made in the areas of the hairpin loop and lower stem internal bulge 
that will allow a compound that selectively binds in this bulged region to disrupt the IRE-IRP 
complex, increasing the rate of ferritin synthesis in the cell.37 
The chemical cleavage agent Ru(tpy)(bpy)O2+ (RuO2+) has been used to find small 
molecules that bind specifically and selectively to the pocket created by the bulged region of 
the ferritin IRE.55  The structure of the IRE has been studied previously using RuO2+ 
oxidation chemistry.51,52  RuO2+ oxidizes solvent accessible guanine nucleobases that are 
prone to cation binding and its small size relative to enzymatic nucleases make it an excellent 
probe of RNA secondary structure.72,73   Four molecules, yohimbine, Hoechst 33285, 
acetopromazine, and promazine, were identified as binding to this bulge region, and 
experimental evidence showed that yohimbine was able to disrupt the human ferritin IRE-
IRP1 complex causing the up-regulation of ferritin protein synthesis in an in vitro translation 
assay.55,74  The binding constant for the IRE hairpin:yohimbine interaction is 4 µM. 
The goal of this research was to examine the ability of promazine, a small molecule 
identified by the RuO2+ footprinting technique, to block the IRP:IRE interaction and 
determine its effect on ferritin protein synthesis.  The hypothesis, based on the ability of 
yohimbine to up-regulate the production of ferritin by binding in the internal bulge region of 
the IRE, was that binding in the internal bulge region by promazine would also disrupt the 
IRP:IRE interaction, allowing ferritin synthesis to be regulated.  
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2.3 Experimental 
2.3.1 Materials 
 Proteinase K (20 mg / ml), phenol/chloroform, acid phenol/chloroform, linear 
acrylamide (5 µg/µl), DEPC-treated water, Superase·In RNase inhibitor (20 U / µl), T7 RNA 
Polymerase PlusTM (200 U / µl), RNase A (1 µg / ml), RNase T1 (1 U / µl), RNase I (100 U / 
µl), alkaline hydrolysis buffer, Gel Loading Buffer II, TURBO DNase I, MEGAshortscriptTM 
T7 Kit, MEGAscriptTM SP6 Kit, MEGAscriptTM T7 Kit and MEGAclearTM transcription 
reaction purification kit were purchased from Applied Biosystems.  Promazine HCl, 
chlorpromazine HCl, promethazine HCl, yohimbine HCl, heparin, desferoxamine, 
dithiothreitol (DTT) and CellLyticTM Y Plus kit (lyticase) were purchased from Sigma-
Aldrich.  T4 DNA ligase, mini Quick Spin RNA Columns, and Complete Protease Inhibitor 
Cocktail Tablets were purchased from Roche.  All restriction enzymes, calf intestinal 
phosphatase (CIP), T4 polynucleotide kinase, T4 RNA ligase, and corresponding buffers 
were purchased from New England Biolabs.  The pUC19K vector was a gift from Robert 
Nicholas of the Department of Pharmacology at UNC-CH.  Novex® Tris-Glycine Gels, and 
NuPAGE® Novex® Bis-Tris Gels were purchased from Invitrogen.  [5’-32P]pCp (0.01 mCi / 
µl), [α-32P]UTP (0.01 mCi / µl), [γ-32P]ATP (0.01 mCi / µl), and Easy Tag EXPRESS-[35S] 
Protein Labeling Mix (0.011 mCi / µl) were purchased from Perkin Elmer.  Ultrafree-MC 
centrifugal filter devices were purchased from Millipore.  Plasmid Maxi and Mini prep kits 
were purchased from Qiagen.  Nonidet P-40® was purchased from USB Corporation.  XL10-
Gold® ultracompetent cells were purchased from Stratagene.  The pGEM®-luc vector, and 
Rabbit Reticulocyte Lysate were purchased from Promega.  Y-PER® Yeast Protein 
Extraction Reagent was purchased from Pierce Scientific.  HiTrap Heparin HP affinity 
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column and HiTrap Q FF ion exchange column were purchased from GE Healthcare.   Dye 
used to determine protein concentration was purchased from Bio Rad.  The pCRII-TOPO 
vector containing the full-length ferritin mRNA sequence (human H-chain; 5’UTR is 268 
bases and contains the IRE) was a gift from Dr. Elizabeth Theil of the Childrens Hospital 
Oakland Research Institute.  IRP1 and IRP2 P. pastoris clones were a gift from Dr. Tracey 
A. Rouault from the National Institute of Child Health and Human Development at the 
National Institutes of Health in Bethesda, MD.            
2.3.2 Methods 
2.3.2.1 Transcription of IRE RNA (50-mer) 
 Creation of vectors used in this project was previously described.55,74  A stock of cells 
carrying the plasmid containing the IRE (50-mer) sequence (referred to here as hIRE) was 
streaked on LB/Kan agar plate.  A single colony was picked and grown overnight in LB/Kan 
media (37°C, with shaking at 250 rpm).  Plasmids were isolated and purified using a Qiagen 
Plasmid Maxi Kit according to the protocol provided by Qiagen.  Final concentration and 
purity of plasmid DNA were determined by the absorbance at 260 nm and 280 nm.  The 
plasmid was digested with Dra I (100 µl; in 1X NEB Buffer # 4, 20 µg hIRE plasmid, 200 U 
Dra I) for 2 h at 37°C, treated with 0.5% SDS and proteinase K (10 µg), for 2 h at 50°C, then 
purified by phenol/chloroform extraction and ethanol precipitation.  To generate the IRE 
RNA a MEGAshortscriptTM T7 Kit was used according to the protocol provided by Applied 
Biosystems, with the addition of 200 U T7 RNA Polymerase PlusTM to increase yields, and  
20 U Superase·In to inhibit RNase degradation.  DNA in the resulting sample was digested 
using 30 U TURBO DNase I at 37oC for 15 min.   Production of the RNA transcript was 
verified on a 15% denaturing (8 M Urea) gel.  The RNA was purified using a mini Quick 
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Spin RNA Column (following the protocol provided by Roche), followed by acid 
phenol/chloroform extraction, and ethanol precipitation.  Absorbance at 260 nm was used to 
determine the final RNA concentration.   
 2.3.2.2 5’ RNA End-labeling 
 RNA (~14 µg) was first dephosphorylated at the 5’ end using 30 U calf intestinal 
phosphatase at 50 oC for 1h.  RNA was then run through a mini Quick Spin Column 
(following the protocol provided by Roche), acid phenol/chloroform extracted, and ethanol 
precipitated.  RNA was 5’ end labeled with 50 – 80 µCi [γ-32P]ATP (0.01 mCi / µl) using 80 
U T4 polynucleotide kinase at 37oC for 1 h.  The kinase was inactivated by heating the 
reaction at 65oC for 20 minutes.  Labeled RNA was then run through a mini Quick Spin 
Column, and ethanol precipitated with linear acrylamide (2.5 µg).  RNA was purified on a 
small 10% (7 M Urea) polyacrylamide gel.  RNA bands were visualized by autoradiography 
and excised from the gel.  Gel slices were crushed and soaked in elution buffer (0.5 M 
NH4OAc, 1 mM EDTA, 0.1% SDS) with Superase·In RNase inhibitor (20 U) in Utrafree-MC 
filters at 37oC overnight.  Samples were spun down at 4,000 x g and ethanol precipitated 
overnight with linear acrylamide (2.5 µg).  The concentration of RNA was determined using 
the absorbance at 260 nm. 
2.3.2.3 3’ RNA End-labeling     
 RNA (30 µg) was 3’ end labeled with 50 – 80 µCi [5’-32P]pCp using 60 U T4 RNA 
ligase overnight at 4oC.  RNA was run through a mini Quick Spin RNA column and further 
purified on a small 10% (7 M Urea) polyacrylamide gel.  RNA bands were visualized by 
autoradiography and excised from the gel.  Gel slices were crushed and soaked in elution 
buffer (0.5 M NH4OAc, 1 mM EDTA, 0.1% SDS) with 20 U Superase·In RNase inhibitor in 
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Utrafree-MC filters at 37oC overnight.  Samples were spun down at 4,000 x g and ethanol 
precipitated overnight with linear acrylamide (2.5 µg).  The concentration of RNA recovered 
was determined using the absorbance at 260 nm. 
2.3.2.4 Internal Labeling of RNA with [α-32P]UTP 
  RNA was transcribed according to the procedure described in Section 2.3.2.1 with the 
addition of 40 – 60 µCi [α-32P]UTP.  Excess radiolabel was removed from the transcribed 
RNA using a mini Quick Spin RNA column, and ethanol precipitated overnight.  RNA was 
further purified on a small 10% (7 M Urea) polyacrylamide gel.  RNA bands were visualized 
by autoradiography and excised from the gel.  Gel slices were crushed and soaked in elution 
buffer (0.5 M NH4OAc, 1 mM EDTA, 0.1% SDS) with 20 U RNase inhibitor in Utrafree-
MC filters at 37oC overnight.  Samples were spun down at 4,000 x g and ethanol precipitated 
overnight with linear acrylamide (2.5 µg).  The concentration of recovered RNA was 
determined using the absorbance at 260 nm.    
2.3.2.5 Expression, Lysis, and Purification of IRP1 and IRP2  
Expression of IRP1 and IRP2 proceeded via the method reported by Allerson et al.,12 
using methanol to activate the alcohol oxidase promoter to induce protein synthesis.   After 
harvesting the yeast, the pellets were stored at -80oC until needed for purification.  Yeast 
pelleted after IRP expression were thawed on ice and resuspended in 2 volumes 
(volume/weight) of breaking buffer (25 mM Tris-HCl, pH 8.0, 20 mM KCl, 1 mM EDTA, 
0.1 M desferoxamine, 0.75 mM DTT, 1 tablet of Complete Protease Inhibitor).  Lysis was 
performed to create spheroplasts using lyticase (1250 U / g cells) from the CellLyticTM Y 
Plus Kit by allowing the reaction to continue until the OD800 nm reached 40% to 60 % of the 
pre-lysed sample reading.  The spheroplasts were disrupted by adding Y-PER® Yeast Protein 
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Extraction Reagent (1875 µl/ 500 mg cells) and agitating at room temperature for 20 min.  
Cells were pelleted at 14,000 x g for 10 min, the lysate was collected and immediately 
subjected to chromatographic purification.   
The purification proceeded in the general manner reported by Allerson et al. with the 
following modification; only two columns, heparin and Q-sepharose, were needed to obtain 
protein purity levels necessary for the subsequently performed experiments.74  
Chromatographic buffers were: Buffer A-no salt (25 mM Tris-HCl, pH 8.0, 0.5 mM EDTA, 
0.1 M desferoxamine, 1 mM DTT) and Buffer B-high salt (25 mM Tris-HCl, pH 8.0, 3 M 
NaCl, 0.5 mM EDTA, 0.1 M desferoxamine, 1 mM DTT).  To decrease degradation by 
proteases, one protease inhibitor tablet was added per 25 ml buffer before use.  
Desferoxamine was used to chelate free iron, and all columns were run at 4oC.  Elution of 
protein from each colum was monitored by absorbance at 280 nm.  Fractions were eluted on 
an ÄKTAprime FPLC system (GE Healthcare) with typical flow rates of 4 ml/min.  Crude 
lysates were first loaded onto a 2 x 5 ml HiTrap Heparin HP column.  The column was 
washed with Buffer A, then eluted with a gradient to Buffer A with 50% Buffer B.  IRP1 
eluted at ~390 mM NaCl and IRP2 eluted at ~525 mM NaCl.  The appropriate fractions (as 
determined by SDS-PAGE) were pooled, diluted to 40 mM NaCl with Buffer A, and loaded 
onto a 1 x 5 ml HiTrap Q Sepharose FF column.  The column was washed with Buffer A 
with 1% Buffer B, and then eluted with a gradient to Buffer A with; 30% Buffer B for IRP1 
and 50% Buffer B 1PR2.  IRP1 eluted at ~ 450 mM NaCl and IRP2 at ~780 mM NaCl.  The 
appropriate fractions were pooled, dialyzed two times against no salt buffer (25 mM Tris-
HCl, pH 8.0, 0.5 mM EDTA), and  concentrated using an Amicon Centricon® Plus 20 
centrifugal filter according to the protocol provided by Millipore.  Protein concentrations 
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were determined with a Bio-Rad protein assay, using BSA as a standard following the 
procedure provided by Bio-Rad.  Samples of protein were stored as 50% glycerol stocks at -
20oC.  The concentration of the IRP1 stock was 1.1 mM, while the concentration of the IRP2 
stock was 19 µM.  Ability of IRP1 and IRP2 to bind to the IRE were evaluated using an 
Electrophoretic Mobility Shift Assay (EMSA). 
2.3.2.6 Electrophoretic Mobility Shift Assay 
 IRE hairpin RNA internally labeled with [α-32P]UTP was transcribed according the 
protocol described in Section 2.3.2.1.   A stock solution of labeled RNA (100 µl; 200 nM 
RNA, in 10 mM HEPES-KOH pH 7.2, 40 mM KCl, 20 U Superase·In) was folded by heating 
to 90oC for 5 min followed by slow cooling to room temperature.  An aliquot of the stock 
solution (5 µl ) containing labeled RNA (~50 nM), binding buffer (10 mM HEPES-KOH pH 
7.5, 40 mM KCl, 0.3% nonidet P-40®, 5% glycerol, 3 mM MgCl2 ), and varying 
concentrations of either yohimbine or promazine (only for drug interaction studies) were 
incubated at room temperature for 20 min.  Concurrently, IRP protein (IRP1 1 µM, IRP2 2 
µM) was incubated with DTT (1 mM) for 20 min.  The two solutions were then mixed, 
heparin (5 µg) was added to prevent any non-specific binding, and incubated for 20 min at 
room temperature.  The reaction was terminated by adding 80% glycerol/bromophenol blue 
dye.  The RNA-protein complexes were separated from unbound RNA on 6% native 
polyacrylamide gels (29:1 acrylamide/bisacrylamide) at 4oC in 1X TBE.  Gels were dried and 
phosphorimaged overnight.  Gels were imaged using a Storm® 860 imaging system.  Band 
intensities were quantified using the ImageQuantTM software package (Molecular Dynamics/ 
GE Healthcare).   
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2.3.2.7 RNase Cleavage Assay 
 Human ferritin IRE RNA (50 base hairpin) was transcribed using a MEGAshortscript 
T7 KitTM according to the procedure described in Section 2.3.2.1.  RNA was 3’-end labeled 
with [5’-32P]pCp using T4 RNA ligase overnight at 4oC as described in Section 2.3.2.3.  
Footprinting solutions were made by adding a trace amount of radiolabeled IRE RNA (~ 0.5 
µM) to a stock solution (100 µl; containing 11 µM unlabeled RNA, in 80 mM Tris-Cl / 20 
mM KCl, pH 7.4).  The RNA solution was then folded by heating to 90oC for 5 min followed 
by slow cooling to room temperature.  Aliquots of the stock solution (5 µl) were used in the 
RNase cleavage reactions.  The footprinting solutions were then incubated with varying 
concentrations of either promazine HCl or yohimbine HCl for 20 min at room temperature (9 
µl total volume).  RNase I (0.001 U, 1 µl) was added and the reaction was allowed to proceed 
for 30 sec before being quenched by adding 5 µl Gel Loading Buffer II.  Samples were 
separated on 20% (7 M urea) polyacrylamide gels, exposed to a phosphorimaging screen 
overnight and analyzed using a Storm® 860 phosphoimager.  Band intensity was quantified 
using ImageQuantTM software.  RNA ladders were constructed using the 3’ labeled RNA via 
enzymatic cleavage by RNase TI, RNase A, and alkaline hydrolysis according to the protocol 
provided by Applied Biosystems.  
2.3.2.8 Transcription of Full-Length mRNA: Human H-chain Ferritin, IRE-luciferase, 
and pGEM®-luciferase 
 The human H-chain ferritin (FL-HF) plasmid encodes for the ferritin gene (1049 
bases) with the IRE sequence in the 5’UTR (286 bases) in the pCRII-TOPO vector under the 
SP6 promoter.  The wild-type plasmid was digested with Xho I (100 µl; containing 40 µg 
FL-HF plasmid, in 1X NEB Buffer #2, 0.1 µg BSA, 200 U Xho I) at 37°C for 2 h, followed 
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by treatment with with 0.5 % SDS, 10 µg proteinase K for 2 h at 50°C, and purification using 
phenol/chloroform extraction and ethanol precipitation.   Concentration of linearized vector 
was determined using the absorbance at 260 nm.   Full length human H-chain ferritin mRNA 
was transcribed from the linearized vector using the SP6 promoter.  Transcription was 
performed using a MEGAscript SP6 KitTM, for 3 h following the protocol provided by 
Applied Biosystems.  Transcribed RNA was purified using a MEGAclear KitTM (according 
to the protocol provided by Applied Biosystems) followed by acid phenol/chloroform 
extraction and ethanol precipitation.  Production of the correct size mRNA was confirmed by 
electrophoresis on a Lonza precast 1.25% agarose RNA gel.  RNA concentrations were 
determined using the absorbance at 260 nm.       
Creation of the IRE-luciferase (IRE-luc) plasmid, containing a 1739 bp fragment 
coding for the luciferase protein with the human ferritin H-chain IRE sequence 18 bases 
upstream of the lucifrease start codon in the pUK19K vector, was described in a previous 
work.55,74  IRE-luciferase mRNA was transcribed from the Xho I linearized vector (digested 
following the protocol described in the above paragraph) using the T7 promoter.  
Transcription was performed using a MEGAscript T7 KitTM following the protocol provided 
by Applied Biosystems.  Transcribed RNA was purified using a MEGAclear KitTM 
(according to the protocol provided by Applied Biosystems) followed by acid 
phenol/chloroform extraction and ethanol precipitation.  Production of the correct size 
mRNA was confirmed by electrophoresis on a Lonza precast 1.25% agarose RNA gel.  RNA 
concentrations were determined using the absorbance at 260 nm.             
The pGEM®-luc vector (wild type luciferase gene under the SP6 promoter) was 
digested with Xho I following the procedure outlined at the beginning of this section.  
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MEGAscript SP6 KitTM, for 3 h following the protocol provided by Applied Biosystems. 
Transcribed RNA was purified using a MEGAclear KitTM (according to the protocol 
provided by Applied Biosystems) followed by acid phenol/chloroform extraction and ethanol 
precipitation.  Production of the correct size mRNA was confirmed by electrophoresis on a 
Lonza precast 1.25% agarose RNA gel.  RNA concentrations were determined using the 
absorbance at 260 nm.       
2.3.2.9 In Vitro Translation of mRNA: Rabbit Reticulocyte Lysate Translation Assay 
 Full length wild-type ferritin, wild-type luciferase, or IRE-luciferase mRNA was 
transcribed as indicated above.  A stock solution of full length mRNA (1 µg/µl in 10 mM 
Tris-HCl, pH 8.0, 1 mM EDTA) was folded by heating the solution to 85 oC for 5 min, 
followed by slow cooling to room temperature.  Translation of mRNA (1 µg) occurred after a 
20 min pre-incubation (10 mM Tris-HCl, pH 8.0, 1 mM EDTA, 30 oC) with or without the 
small molecule for 20 min at 30oC using Rabbit Reticulocyte Lysate and [35S]methionine 
according to the protocol provided by Promega (final reaction volume 12.5 µl).  Synthesized 
protein was analyzed by electrophoresis on 16% Tris-Glycine gels in Tris-Glycine SDS 
buffer (pH 8.3).  The gels were fixed in a 50% methanol/ 10% acetic acid solution and 
exposed to a phosphorimaging screen overnight.  Protein band intensities were quantitated 
based on [35S]methionine incorporation using ImageQuantTM software.   
A competition assay with two mRNAs, wild-type ferritin and wild-type luciferase, 
was used to determine the specificity of promazine for the IRE in a more complex mixture.  
The procedure was identical to the above, except that 1µg of each RNA was preincubated in 
solution with promazine before the addition of lysate.  
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2.4 Results and Discussion 
2.4.1 Small Molecule:Ferritin mRNA Interaction: RNase Cleavage Assay 
Previous work has identified commercially available small molecules that bind near 
the internal bulge of the ferritin IRE using the chemical cleavage agent Ru(tpy)(bpy)O2+.55  
Ru(tpy)(bpy)O2+ cleaves solvent accessible guanines in nucleic acids, and small molecule 
binding causes inhibition of this cleavage.55,68,75,76  Compounds identified were those that 
inhibited guanine oxidation near the internal bulge of the IRE structure, while guanine 
oxidation of the hairpin loop remained constant.  Thirteen compounds were initially 
screened, and four of these, yohimbine, Hoechst 33258, promazine, and acetopromazine, 
showed favorable binding characteristics; selective inhibition of the cleavage at G23 and G27 
guanines near the internal bulge of the IRE structure, with little effect on the cleavage at G16 
found in the hairpin loop.55  The structures of these compounds are shown in Table 2.1.  
Yohimbine and Hoechst 33258 were further screened for their ability to block the IRP:IRE 
interaction.  Hoechst 33258 was shown to indiscriminately bind to all areas of the IRE RNA 
and was used only as a non-specific binder in future studies.55,74  The natural product 
yohimbine displayed ideal binding characteristics, binding only in the stem/bulge region of 
the IRE.  Enzymatic footprinting with RNase I was used to confirm the results of 
Ru(tpy)(bpy)O2+ footprinting (Figures 2.5 and 2.6).  RNase I cleaves equally after all four 
nucleotides, exhibits reproducible cleavage patterns, and has been used previously to 
footprint RNA binding sites.65,66  As expected, both promazine and yohimbine showed an 
inhibition of cleavage in the area of nucleotides 21-25, with no change in cleavage intensity 
seen in the hairpin loop region (Figure 2.7 ).  This finding confirms the viability of the 
Ru(tpy)(bpy)O2+ assay as an RNA-ligand screen.  Due to the variability in the sequence and 
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base-pairing surrounding the C8 found mid-helix, targeting drugs to this region provided an 
increased selectivity for the ferritin IRE compared to IREs found in other mRNAs.9,44,46    
2.4.2 Effect of Promazine on the IRP:IRE Interaction: Electrophoretic Mobility Shift Assay 
Protein-nucleic acid interactions are commonly studied using the observation that 
protein:nucleic acid complexes migrate more slowly in a native polyacrylamide gel than 
nucleic acids alone.  By observing the retardation of a radiolabeled nucleic acid strand when 
it is bound to the much larger protein compared to the free nucleic acid one can determine if 
a protein or mixture of proteins is capable of binding to a given nucleic acid sequence.  This 
experiment is known as an electrophoretic mobility shift assay (EMSA) and can also be 
referred to as a gel shift assay, gel mobility shift assay, band shift assay, or gel retardation 
assay.  We used this type of assay to determine the effect of promazine on the IRP:IRE 
interaction using radiolabeled IRE RNA and purified IRP1 and IRP2 proteins.  The IRP:IRE 
interaction has been previously studied using EMSA to elucidate the structure and sequence 
constraints for high affinity binding of IRP1 and IRP2 with the IRE.9,44,54,77,78  These studies 
have revealed that the determinants for binding are similar for the two proteins, but not 
exactly the same.  Both proteins are able to bind the wild type IRE sequence with similar 
affinity5,44, but sequences were identified that specifically bind to either IRP1 or IRP2.      
Here, gel shift analysis was used to detect the activity of the purified IRP1 and IRP2 
proteins and the disruption of the IRP:IRE interaction by promazine and yohimbine.  At 
constant IRP and IRE concentrations, increasing concentrations of small molecule were 
added, and the resulting IRP:IRE complexes were observed on a native polyacrylamide gel 
(Figures 2.8A, 2.9A, 2.10A and 2.11A).  Quantitations of the bands revealed an approximate 
increase in free RNA of about 25% for promazine at 50 µM with IRP1 (Figure 2.8B), and 
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7% for IRP2 (Figure 2.9B).  Yohimbine showed an increase in free RNA of 12% for IRP1 
(Figure 2.10B) and 4% with IRP2 (Figure 2.11B)at a concentration of 50 µM.  Variations in 
binding and quantitation result from impurities in the purified protein.  Two conclusions can 
be drawn from these results.  First, both promazine and yohimbine are able to displace a 
limited amount of IRP1 and IRP2 from the IRE.  Second, there may be an additional 
population of a ternary complex formed involving IRE, IRP, and small molecule.  This 
complex was first suggested by Tibodeau74 to explain the positive translation assay results 
with saturating concentrations of yohimbine.  These same positive translation assay results 
are seen in the presence of promazine (see section 2.4.3).  This new evidence suggests that 
using a small molecule to disrupt the IRP:IRE interaction is more complex than first thought.       
A crystal structure of the interaction between bullfrog ferritin IRE RNA and rabbit 
IRP1 shows that contacts occur between the protein and RNA at two separate sites.37  Direct 
protein:RNA contacts are made in the areas of the hexaloop and the RNA lower stem with 
protein binding centered around the C8 nucleotide.  The conservation of the IRE structure 
and sequence across species allows us to use this crystal structure to explain our experimental 
results.  The binding of the IRE through these two separate binding sites contributes to the 
specificity of the IRP:IRE interaction.  It is also shown that these two areas contain the bases 
that have been shown to interact specifically with yohimbine and promazine in the human 
ferritin IRE RNA.  Disrupting the binding at either site with a small molecule would cause a 
weakened IRP:IRE interaction that would allow the ribosome to scan through this area and 
increase the amount of ferritin biosynthesis.  If the structural change due to this binding was 
not large enough to displace all binding, it would be possible for ferritin synthesis to occur, 
albeit at a decreased rate.   
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2.4.3 Regulation of Protein Synthesis by Small Molecules: In Vitro Translation Assay 
2.4.3.1 Ferritin Translation  
 IRP proteins were first identified as repressors of ferritin synthesis when it was noted 
that ferritin mRNAs translate very poorly in rabbit reticulocyte lysates (RRL) relative to 
other RNAs, and that this deficiency was not seen in wheat germ lysates.31  A repressor 
protein, now known as IRP1, that bound the IRE was purified from the reticulocyte lysate.  
Since then, reticulocyte lysates have been used to assess translation of ferritin and other iron-
related transcripts in the presence of IRPs.5,46  We wanted to use this system to determine 
whether promazine could retain its IRE-binding ability in a more complex in vitro translation 
mixture, by competing for binding of the IRP.   
A time-course translation assay was performed to ensure that ferritin synthesis rates 
were linearly dependent on incubation length at the chosen time (20 min).  In addition to the 
wild-type ferritin mRNA, the effect of promazine on the regulation of two other sequences 
were studied:  luciferase mRNA which contains no regulatory sequence, and IRE-luc, 
containing the human H-chain ferritin IRE regulatory element 18 bases upstream of the 
luciferase gene.  Representative SDS-PAGE gels for the three translations are shown in 
Figure 2.12.  Promazine, like yohimbine, was able to increase the rate of ferritin synthesis in 
the in vitro translation system. The wild-type ferritin mRNA translation was increased by 
66% in the presence of promazine compared to 40% in the presence of yohimbine.55,74  The 
positive up-regulation of ferritin synthesis by promazine occurs at lower concentrations than 
yohimbine, indicating tighter binding of promazine to the IRE RNA, which is consistent with 
the gel mobility shift assay and RNase footprinting experiments.  At high concentrations of 
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promazine, a decrease in overall translation occurs for all transcripts tested.  This is most 
likely due to promazine interacting with the translational machinery in the RRL.     
2.4.3.2 IRE-luciferase and Wild-type Luciferase Translation  
 To determine if the results observed with the increase of ferritin synthesis by 
promazine were dependent on the identity of the transcript, mRNA encoding luciferase with 
the IRE upstream of the start codon was used.  This construct is still able to bind to IRPs 
indicating that its synthesis should be modulated by promazine binding.74  After a time-
course assay to determine the linear region for IRE-luciferase translation, the assay was 
repeated in the presence of promazine.  Translation in the RRL showed that the promazine 
interaction with the IRE-luciferase RNA caused an increase in synthesis of the luciferase 
protein by about 70 % over baseline levels. (Figure 2.13)  In contrast, there was no 
significant change in the amount of wild-type luciferase translated with the addition of 
promazine, even at high concentrations.  These results were very similar to the ferritin results 
where a 66% increase was seen.  The reported value for the yohimbine interaction is an 
increase of 40%.55,74  This result, with the earlier ferritin findings, indicates that the observed 
up-regulation in the presence of promazine does not depend on the identity of the mRNA, but 
instead is a direct result of the IRE-small molecule interaction.  It also supports the 
hypothesis that promazine binds to the IRE tighter than yohimbine.   
2.4.3.3 Ferritin and Wild-type Luciferase Competition Assay 
  Once it was established that promazine was able to increase the synthesis of protein in 
the presence of an IRE, we wanted to determine its ability to specifically increase production 
of one protein in a mixture of mRNAs.  To test this we used the same RRL assay, with a 
modified procedure: the promazine was pre-incubated with both ferritin mRNA containing 
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an IRE and wild-type luciferase which contains no regulatory element.  Translation in the 
RRL showed that there was little discernable change in the synthesis of either protein in the 
presence of promazine, with a possible repression of ferritin synthesis occurring at higher 
concentrations (Figure 2.14)  At the highest concentration of promazine used, both luciferase 
and ferritin protein translation were inhibited indicating that promazine was affecting the 
translational machinery.  This decrease in synthesis was also seen in the other translation 
experiments at high promazine concentrations.  
2.4.4 Binding Constant Determination 
 Determination of another measurement of selectivity, the binding constant (Kd) for 
the promazine-RNA interaction was attempted by various methods.  Our initial attempts 
included: luminescence spectroscopy, surface plasmon resonance (SPR), fluorescence 
polarization anisotropy, and absorbance spectroscopy.  Binding constant data can also be 
determined using electrophoretic mobility shift assays.  However, due to the impurities in the 
purified IRP proteins, a reasonable binding constant could not be determined from this data.  
A binding constant range was determined by fitting a 1:1 binding isotherm (Equation 1) to 
the RNase I cleavage data. 
 
(1)    
1)][(
1
+= KdRNAAY  
    
From the data a two binding event model was predicted, with the first binding event 
occurring around 30 nM, and the second around 3.5 µM.  Because these values are derived 
from RNase cleavage data, it can not be determined if the first binding constant represents an 
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actual binding event or a structural rearrangement of the RNA due to an interaction of the 
positively charged molecule with the negatively charged phosphate backbone.  It is also 
possible that there is more than one molecule of promazine binding to the IRE at higher 
concentrations.  However, evidence for this was not seen in any of the completed footprinting 
experiments.  The binding constant for yohimbine with the ferritin IRE 50-mer was 
determined to be 4 µM.55,74  The results of the in vitro translation assays where ferritin 
synthesis is up-regulated at lower concentrations of promazine compared to yohimbine 
supports the tighter binding of promazine and the determined binding constant range.  Many 
small molecules that bind to RNA have been shown to interact in this low micromolar 
range.79-84  These include RNAs selected via SELEX85-87 (systematic evolution of ligand by 
exponential enrichment) for a specified interaction, and the TAR RNA element found in 
HIV-1.88  Promazine has been shown to interact with TAR RNA in a bulged site that is 
important for Tat protein binding with a binding constant of > 5 mM.89-91   
   
2.5 Conclusions 
 Two main conclusions can be drawn from these experiments.  First, the use of the 
Ru(tpy)(bpy)O2+ footprinting method as an assay for small molecule-RNA binding was 
validated through the use of an RNase cleavage method.  The area identified as interacting 
with the small molecules by Ru(tpy)(bpy)O2+ oxidation also showed reduced cleavage in the 
RNase method.  Second, binding of small molecules to specific three-dimensional structures 
in mRNA can alter protein synthesis.   The modulation of gene expression through the 
targeting of mRNA with small molecules has previously been shown,85,86 but all prior 
molecules have resulted in a down-regulation of protein synthesis.  To our knowledge the up-
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regulation of ferritin synthesis by the addition of promazine and yohimbine is the first 
reported case of enhancement of gene expression by small molecules.  However, this up-
regulation is likely to be seen where a protein:RNA interaction, such as the IRP:IRE 
interaction, blocks formation of the translation initiation complex.  Disruption of the complex 
would allow ribosome scanning and protein synthesis.  
 These studies indicate that promazine binds to the ferritin IRE selectively, and this 
binding event up-regulates the synthesis of ferritin through the disruption the IRP:IRE 
interaction.  There are three main possibilities for the origin of this result.  First, the free 
RNA generated by promazine blocking the IRP:IRE interaction is responsible for the 
increase in translation.  Second, a ternary complex formed between promazine, IRP, and 
RNA, can be translated, unlike the IRP:IRE complex.  Third, the increased synthesis seen 
could be a combination of these two events.  It would be difficult to ascertain the absolute 
level of synthesis occurring in the lysate that would be needed to sort out which of these 
three possibilities is occurring.  Additionally, in a more complex mixture of two RNAs, one 
containing a regulatory element and one without an element, addition of promazine does not 
detectably increase the rate of ferritin synthesis at any concentration, suggesting that 
considerably greater selectivity would be required to achieve up-regulation of gene 
expression in vivo.  Nonetheless, these results point to the feasibility of specific RNA-small 
molecule interactions as modalities for up-regulation. 
There are two potential means by which a small molecule binding to RNA could 
disrupt the protein-RNA interactions.  Binding could occur in the RNA minor groove and 
block the ability of the proteins to make specific contacts, or binding could occur in an 
intercalative manner, causing a disruption in base pairing or stacking, -- resulting in a change 
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in secondary or tertiary structure.  Promazine binding to HIV-1 TAR RNA, which contains a 
structural element similar to the IRE hairpin, has been studied by the James group.15  They 
identified the binding of promazine to possess some intercalative qualities, although the non-
planar structure of phenothiazine prevents binding solely by intercalation.  Binding through a 
semi-intercalative manner would cause distortion in the helical stem area of the IRE and 
disrupt its secondary structure.  This could prevent contacts from being formed correctly 
between the IRP protein and IRE RNA suggested by the crystal structure.  It is likely a 
combination of both the disruption of essential protein contacts and the distortion of the IRE 
structure by promazine and yohimbine that causes the increase protein synthesis levels shown 
in this work.    
 More work is needed in the drug discovery aspect of this project.  Although two 
promising small molecules were identified from the Ru(tpy)(bpy)O2+ footprinting screen, 
these compounds were not selective in a more complex system.  With the advances in 
computer aided drug discovery, this method could be used to aid in the search for a small 
molecule with favorable binding characteristics.  With a crystal structure of the IRP:IRE 
interaction now available, the specific contacts that need to be inhibited have been identified.  
Using the available NMR structure of the IRE RNA a database of available chemicals could 
be screened for binding to the three-dimensional RNA structure.  Once identified, the small 
molecules could then undergo a footprinting method to validate their ability to bind in the 
desired region.   
 A second future direction of this project would be to test a phenothiazine library as 
well as derivatives of yohimbine to determine modifications to the small molecule that would 
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enhance the selectivity and specificity of binding.  Small regulatory RNAs (small interfering 
RNAs and microRNAs) could also be evaluated for their ability to regulate translation.   
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2.6 Tables 
Table 2.1. Names and structures of compounds found to interact with the IRE through 
the RuO2+ assay. 
Compound Name Structure 
Yohimbine 
 
Hoechst 33258 
 
Promazine 
 
Acetopromazine 
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2.7 Figures 
 
Figure 2.1. Cellular iron transport: the transferrin cycle.  Schematic showing the receptor-
mediated endocytosis pathway used for cellular iron transport.  Holo-Tf binds to the 
transferrin receptor.  Receptors are brought into the cell via clathrin-coated pits.  Once inside 
the cell specialized endosomes form and become acidified through proton pumps.  The pH 
change causes a conformational change in the transferrin protein and iron is released.  Iron is 
exported out of the endosome by DMT-1.  Iron that is not immediately used by the cell is 
stored in ferritin.   Subsequently, apo-transferrin and the transferrin receptor are returned to 
the cell surface where they dissociate at neutral pH.  The recycled apo-transferrin and 
transferrin receptor can be involved in numerous cycles of iron transport. Adapted from 
Andrews.15   
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Figure 2.2. Sequence and structures of the human ferritin iron responsive element (IRE).  A) 
Secondary structure of the human ferritin IRE predicted by mfold.92,93  The base pair between 
C14 and G18 is indicated.  B) NMR structure of the human ferritin IRE.33  The important 
residues in the structure are indicated.  Blue residues are those found in the hairpin loop, 
while residues in green are those found in the internal bulge.  (PDB accession number 
1AQO) C) Sequence of the human ferritin IRE (50-mer) used in this study.  Bases in bold are 
found in the hexaloop.   
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Figure 2.3.  Schematic representation of ferritin translation regulation by IRP binding.  In 
iron-depleted cells, IRP binding to the IRE in the 5’ UTR interferes with translation 
initiation.  In iron-replete cells the IRP does not bind the IRE and the ribosome can translate 
the mRNA.  This type of regulation is also seen in mammalian mitochondrial aconitase, and 
erythroid amino levulinic acid synthase. Adapted from Rouault.33     
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Figure 2.4. Schematic representation of transferrin receptor translation regulation by IRP 
binding.  In iron-depleted cells, IRP binding to the IREs in the 3’ UTR protects the mRNA 
from endonucleolytic cleavage, increasing mRNA stability.  Protein can then be translated.  
In iron-replete cells the IRP does not bind the IRE leaving the mRNA susceptible to nuclease 
cleavage.  This type of regulation is also seen in DMT-1. Adapted from Rouault.33 
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Figure 2.5. Effect of promazine on RNA cleavage by RNase I in human IRE RNA.  Lane 1, 
alkaline hydrolysis ladder; lane 2, a C/U ladder generated using RNase A; lane 3, a G ladder 
generated using RNase T1; lane 4, RNA alone.  Lanes 5-21, [RNA] = 5.6 uM , [RNase I] = 
0.001 U.  Lanes 5-21 contain promazine concentrations (µM) as follows: lane 5, 0; lane 6, 
0.0025; lane 7, 0.005; lane 8, 0.01; lane 9, 0.025; lane 10, 0.05; lane 11, 0.1; lane 12, 0.25; 
lane 13, 0.5, lane 14, 1.0; lane 15, 5.0; lane 16, 10.0; lane 17, 25.0; lane 18, 50.0; lane 19, 
75.0; lane 20, 100.0; lane 21, 2000.0.    
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Figure 2.6. Effect of yohimbine on RNA cleavage by RNase I in human IRE RNA.  Lane 1, 
alkaline hydrolysis ladder; lane 2, a C/U ladder generated using RNase A; lane 3, RNA 
alone.  Lanes 5-20, [RNA] = 5.6 uM , [RNase I] = 0.001 U.  Lanes 5-21 contain yohimbine 
concentrations (µM) as follows: lane 5, 0; lane 6, 0.0025; lane 7, 0.005; lane 8, 0.01; lane 9, 
0.025; lane 10, 0.05; lane 11, 0.1; lane 12, 0.25; lane 13, 0.5, lane 14, 1.0; lane 15, 5.0; lane 
16, 10.0; lane 17, 25.0; lane 18, 50.0; lane 19, 75.0; lane 20, 100.0; lane 21, 2000.0.     
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Figure 2.7. Effect of promazine (A) and yohimbine (B) on RNase I cleavage of the stem 
region of human IRE RNA.  Decrease in cleavage at higher small molecule concentrations 
indicates binding in the stem region.  Quantitations are from one experimental trial using 
ImageQuantTM software and are normalized to the C14 residue.  Legend values on the right 
indicate final concentration of small molecule in the assay.  Data represents one cleavage 
experiment.    
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Figure 2.8. Effect of promazine on the IRP1:IRE interaction.  A) Electrophoretic mobility 
shift assay.  [RNA]= 50 nM.  [IRP1]= 1 µM. B) Quantitation of [32P] RNA bands.  Legend 
values indicate the final small molecule concentration in the assay.  An overall increase in 
unbound RNA is seen with increasing concentrations of promazine.  Data represents one 
trial.                
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Figure 2.9. Effect of promazine on the IRP2:IRE interaction.  A) Electrophoretic mobility 
shift assay.  [RNA]= 50 nM.  [IRP2]= 2 µM. B) Quantitation of [32P] RNA bands.  Legend 
values indicate the final small molecule concentration in the assay.  An overall increase in 
unbound RNA is seen with increasing concentrations of promazine.  Data represents one 
trial.  
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Figure 2.10. Effect of yohimbine on the IRP1:IRE interaction.  A) Electrophoretic mobility 
shift assay.  [RNA]= 50 nM.  [IRP1]= 1 µM. B) Quantitation of [32P] RNA bands.  Legend 
values indicate the final small molecule concentration in the assay.  An overall increase in 
free RNA is seen with increasing concentrations of yohimbine. Data represents one trial.   
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Figure 2.11. Effect of yohimbine on the IRP2:IRE interaction.  A) Electrophoretic mobility 
shift assay.  [RNA]= 50 nM.  [IRP1]= 1 µM. B) Quantitation of [32P] RNA bands.  Legend 
values indicate the final small molecule concentration in the assay.  An overall increase in 
free RNA is seen with increasing concentrations of yohimbine.  Data represents one trial. 
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Figure 2.12.  In vitro translation assay to determine the effect of promazine on protein 
translation.  [35S]methionine SDS-PAGE gel depicting translation of (A) wild-type ferritin 
mRNA, (B) IRE-luciferase mRNA, and (C) wild-type luciferase mRNA. [mRNA]= 1ug.  
[promazine]: Lane 1, 0 µM; Lane 2,0.5 µM; Lane 3, 1 µM; Lane 4, 10 µM; Lane 5, 20 µM; 
Lane 6, 40 µM; Lane 7, 80 µM.    
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Figure 2.13. Effect of promazine on IRE-dependent mRNA translation in cell-free extracts 
as measured by incorporation of [35S]methionine.  Data are representative of at least three 
different trials on at least two separate preparations of RNA.  These results are expressed as a 
percentage of the control (no promazine added, normalized to 100%), and the error bars 
represent standard deviation.     
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Figure 2.14. Effect of promazine on the translation of a mixture of ferritin and luciferase 
mRNA in cell-free extracts as measured by incorporation of [35S]methionine.  The reactions 
contained 1 µg each of ferritin and luciferase mRNA.  Data are representative of at least three 
different trials on at least two separate preparations of RNA.  These results are expressed as a 
percentage of the control (no promazine added, normalized to 100%), and the error bars 
represent standard deviation.     
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 Chapter 3 
Identification of Small Molecules that Target RNA and Mediate Human 
Preproinsulin Protein Synthesis 
 
3.1 Abstract 
 Insulin resistance and deficiency in insulin secretion are the main causes of diabetes 
mellitus, making the ability to regulate insulin synthesis an area of great interest.  Two forms 
of the 5’ untranslated region (UTR) of the human preproinsulin mRNA exist, a native form 
(NAT), and a splice variant form (SPV) that is up-regulated in response to chronic glucose 
stimulation.   To investigate the ability of small molecules to modulate preproinsulin 
synthesis, small molecules that bind to 5’UTR of the human preproinsulin mRNAs were 
identified, and their effect on protein synthesis was determined.  The secondary structure of 
the NAT and SPV 5’UTR was examined using RNase cleavage, and the transition metal 
complexes Ru(tpy)(bpy)O2+ (RuO2+, bpy = 2,2’-bipyridine, tpy = 2,2’,2’’-terpyridine), and 
Ru(bpy)32+.  RuO2+ and Ru(bpy)32+ are chemical nucleases that oxidize guanine bases in 
RNA sequences.  The ability of small molecules to bind to, or change the secondary structure 
of, the 5’UTR of the preproinsulin mRNAs was investigated using the same techniques.  Two 
small molecules, neomycin B and kanamycin B, have been identified as binding to the 
mRNAs using these screening methods.  An in vitro translation system showed that these 
small molecules decreased the amount of preproinsulin protein synthesized for both the 
native and splice variant forms of mRNA.      
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3.2 Introduction 
3.2.1 Regulation of Glucose Homeostasis 
 Glucose is required as a metabolic fuel by the brain under physiologic conditions 
while other organs use fatty acids as well as glucose to generate energy.  Plasma glucose 
concentrations are maintained within a narrow range; the production, uptake and utilization is 
regulated by an intricate network of hormones, neural pathways and metabolic signals.  
Insulin, a peptide hormone, is produced in the β-cells of the pancreatic islets in response to 
glucose and is the key regulator of glucose homeostasis.   
The body’s major source of glucose is the diet.  In the fasting state, plasma glucose 
levels are maintained primarily by the breakdown of glycogen in the liver, and the production 
of glucose in the liver and kidneys.1  Low insulin levels cause decreased glycogen synthesis, 
reduce glucose uptake into insulin-sensitive tissues, and promote mobilization of stored 
precursors.  Post-prandially, glucose elicits a rise in insulin secretion from β-cells, reversing 
the processes identified above.  Insulin enhances cellular glucose uptake by increasing the 
number of glucose transporters in the plasma membrane of all cells.1  Once inside the cell, 
the transported glucose is either used as metabolic fuel or promotes energy storage by 
conversion of cellular substrates into glycogen, triglycerides, and proteins.  Abnormalities in 
insulin secretion lead to misregulation of plasma glucose levels resulting in the disease 
diabetes mellitus.2,3   
There are two broad categories of diabetes mellitus, type 1 and type 2.4  Type 1 
diabetes results in the lack of, or severe reduction in insulin secretion due to autoimmune 
destruction of pancreatic β-cells.4  Current treatment by administration of insulin does not 
prevent long-term complications including failure of major organs.3  Type 2 diabetes is the 
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more prevalent form in society.  It is a multifactorial polygenic disease, though the 
mechanism is currently not understood.2,4,5  The pathogenesis involves progressive 
development of insulin resistance, a relative deficiency in insulin secretion, and increased 
glucose production.4  Much work is being put into understanding insulin regulation and its 
effects on the body.     
3.2.2 Insulin 
3.2.2.1 Human Insulin Biosynthesis 
 Expression of the insulin gene by pancreatic β-cells is mediated by a number of 
circulating nutrients and hormones, of which glucose is the predominant physiological 
stimulus.6    Mature human insulin is a 6 kDa peptide-hormone produced in the β-cells of the 
pancreatic Islets of Langerhans.7-10  It is made up of two polypeptide chains, the A- (21 
amino acids) and the B-chain (30 amino acids) connected by two disulfide bonds (residues 
A7 to B7, and A20 to B19)8,9 (Figure 3.1).  The A-chain also contains an internal disulfide 
bridge (residues A6 to A11)8,9.  The positions of these disulfide bonds do not vary across 
mammalian species.9   
Insulin is initially synthesized as a single-chain, 86-amino-acid precursor polypeptide, 
known as preproinsulin, which undergoes subsequent proteolytic processing to create the 
hormone insulin (Figure 3.2).4,11  Preproinsulin is first converted to proinsulin, and later to 
mature insulin by proteases.  Preproinsulin is a 12 kDa protein that contains a 24 residue N-
terminal signal peptide, characteristic of proteins that enter the secretory pathway.12-14  The 
signal sequence facilitates transit into the lumen of the rough endoplasmic reticulum 
(RER).15  This signal peptide is cleaved cotranslationally in the RER, generating proinsulin.16  
Proinsulin is a 9 kDa protein that contains the A- and B- chain peptides of insulin, joined by 
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a connecting C-peptide (31 amino acids).17  The C-peptide is thought to aid in the folding of 
the molecule, allowing for the correct formation of disulfide bridges.  It is also packaged in 
the vesicles and co-secreted with mature insulin.  There is considerable variation in the 
sequence of the C-peptide between species, and its exact function is unknown.8,17,18  After 
being produced in the RER, proinsulin is transferred into the cis-Golgi, where it is sorted 
along with its processing enzymes and other components through the trans-Golgi into 
clathrin coated secretion granules.16,19  Maturation of this granule involves the removal of the 
proinsulin C-peptide by prohormone convertase (PC) 1/3 and PC2 as well as 
carboxypeptidase E/H.3,20  PC1/3 and PC2 are trypsin-like endoproteases that cleave at 
dibasic sites.21  PC2 shows preference for cleavage at the A-/C-chain junction while PC1/3 
cleaves at both sites with a preference for the B-/C-chain junction.22  Carboxypeptidase E/H 
is an exopeptidase that removes C-terminal basic residues after cleavage by PC2 and 
PC1/3.17  The mature secretory granules are stored in β-cells until their fusion with the 
plasma membrane is stimulated by secretory signals.   
3.2.2.2 Insulin Secretion from Pancreatic β-cells 
Under normal conditions, only a small portion of stored insulin is released after each 
meal, even under maximum stimulation.3  This allows for the replenishment of the stored 
pool of insulin and maintenance of constant insulin content in β-cells.  Insulin secretion is 
regulated primarily by changes in blood glucose levels.  Uptake and metabolism of glucose 
in β-cells generates intracellular signals for insulin secretion and activates the electrical 
activity of β-cells.2  Glucose regulates the β-cell electrical activity through changes in the 
activity of ATP-sensitive K+ (K+ATP) channels.23  Glucose is brought into the β-cell through 
the glucose transporter GLUT2, which allows entry via facilitated diffusion, and a rate of 
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influx proportional to its extracellular concentration.  Once inside the cell, glucose is 
phosphorylated to glucose-6-phosphate by glucokinase.  Further metabolism of glucose leads 
to an increase in the ATP/ADP ratio causing closure of K+ATP channels.24  Closure of these 
channels leads to a depolarization of the plasma membrane, and initiation of β-cell electrical 
activity leading to the opening of voltage gated Ca2+ channels.10,25  The influx of Ca2+ ions 
results in an increased intracellular concentration that triggers fusion of the vesicles 
containing the stored insulin pools to the plasma membrane.  Although other hormones are 
able to increase the intracellular Ca2+ concentration, they do not induce insulin secretion in 
the absence of glucose.3  Insulin secretory profiles reveal a pulsed pattern of hormone 
release, with small bursts occurring about every 10 min, with larger amplitude oscillations 
occurring every 80 to 150 min.4  Meals or other major stimuli of insulin secretion induce 
large (four- to five-fold increases over baseline) bursts that usually last 2 to 3 h before 
returning to baseline.   
3.2.2.3 Mechanism of Insulin Action in the Body 
 Once insulin is released into the venous system ~50% is degraded by the liver.4  The 
remaining insulin binds to insulin receptors in target sites.  The insulin receptor is a 
heterotetrameric protein consisting of two extracellular α subunits and two transmembrane β 
subunits.26-28  The β subunits contain an intrinsic tyrosine kinase activity that is stimulated by 
binding of insulin to the α subunit.  Upon insulin binding, the receptors autophosphorylate 
and activate their kinase activity, allowing binding of downstream signaling molecules.29-32  
These molecules are involved in a variety of signaling cascades that are involved in gene 
expression, glycogen and protein synthesis, and lipogenesis.4  An example of one of the 
pathways activated is the phosphatidylinositol-3’-kinase (PI-3-kinase) pathway that 
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stimulates the translocation of glucose transporters such as GLUT4 to the cell surface.  These 
transporters move circulating glucose from the plasma into muscle, hepatic and adipose 
tissues.33,34  Attenuated GLUT4 translocation and glucose uptake by muscle and fat cells 
following insulin stimulation represent a prime defect observed in insulin resistance.5  The 
mechanism underlying insulin-mediated regulation of glucose concentration is dependent on 
glucose itself regulating insulin biosynthesis and secretion.  
3.2.3 Control of Insulin Gene Expression by Glucose 
 In humans, a single insulin gene is located on chromosome 11 and was first 
sequenced by Bell and coworkers in 1980.11,35  The gene consists of three exons and two 
introns, with the coding region starting in exon 2.  In this manner, exon 1 and part of exon 2 
comprise the 5’UTR of human insulin.11  Expression of the insulin gene in adult humans is 
restricted to the islet beta-cell, and is regulated at both the transcriptional and translational 
levels.36-38  In the short term (< 2 h), glucose-induced proinsulin synthesis is regulated at the 
translational level.38,39  During longer periods of glucose stimulation (> 6 h), there is an 
additional element of transcriptional control and an increase in mRNA stability.38,40,41   
           Positive and negative regulation of insulin gene transcription relies on the interaction 
of sequence motifs in the promoter with islet cell specific transcription factors.  There are a 
number of cis-acting DNA elements and trans-acting factors involved in regulating insulin 
gene transcription including glucose.6,36,42-44  Inducible transcription most likely depends on 
sequences in the promoter and/or enhancer region that control the cell-type specificity of the 
insulin gene.36  It has been suggested that factors binding to sites in this region are modulated 
by glucose, although the mechanism is not well understood.45-47  Increasing glucose 
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concentration 10-fold has been shown to increase the level of preproinsulin mRNA in cells 
2.3-fold.42  
 Glucose-mediated insulin protein synthesis is predominately regulated through 
control of preproinsulin translation at the post-transcriptional level, however the mechanism 
is not well understood.  It is known that insulin production parallels insulin secretion to 
maintain intracellular stores.48  Glucose stimulates general protein synthesis in β-cells 
approximately 2-fold49, while glucose-stimulated proinsulin synthesis can be increased up to 
10-fold.39,45,50  Glucose exerts its effects largely through mechanisms requiring specific 
sequences in the UTRs of preproinsulin mRNA, especially in the 5’UTR.13,14,20  Examples of 
these processes are the up-regulation of general translation initiation factor activity, the rate 
of translational elongation, and signal recognition particle effects.50-52  The preproinsulin 
5’UTR is predicted to form a stem loop structure similar to the 5’UTR of the ferritin 
mRNA.53   
The 5’UTR of the human and mouse insulin genes contain a secondary structural 
element which can exist in two forms: a native preproinsulin mRNA form (NAT), and a 
preproinsulin splice variant (SPV) (Figure 3.3).54,55   The splice variant mRNA has shown 
increased translational efficiency over the native constructs in both human and mouse islet 
cells.54,55  In humans it was shown that the alternatively spliced mRNA was induced 10-fold 
in times of chronic glucose stimulation.  Recently, an 8 nt region of the native preproinsulin 
5’UTR, called the preproinsulin mRNA glucose-responsive translation element (ppIGE, 
glucose regulatory element), was found to specifically bind an unidentified factor present in 
the islets of Langerhans (referred to here as ppIGE regulatory factor).37  This interaction has 
been shown to be a key component of the glucose-mediated regulation of insulin production.  
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While the exact binding effect of this factor is unknown, it is believed that binding has an 
inhibitory effect upon translation, similar to what is seen in the human ferritin system 
discussed in Chapter 2.37  When this 8 nt region is disrupted either by mutagenesis or as in 
the SPV mRNA, glucose stimulated proinsulin biosynthesis was abolished.  Production of 
this SPV mRNA is up-regulated only in times of chronic glucose stimulation, such as 
hyperglycemia. This may indicate that the normal glucose-regulated proinsulin synthesis 
could be circumvented in times of high insulin need.37  Identifying a small molecule that 
could bind to this region in the NAT mRNA would help determine whether binding of the 
ppIGE binding factor stimulates or inhibits insulin biosynthesis.   
3.2.4 Identification of Small Molecules that Bind to Human Preproinsulin mRNA 
 Chemical and enzymatic footprinting methods can be used to identify precise binding 
sites of small molecules on an RNA target.56-62  Previously a RuO2+ footprinting method was 
used to identify small molecules that bound specifically and selectively to the iron responsive 
element (IRE) in human ferritin mRNA.56,57  Another nucleic acid oxidation method, the 
flash-quench reaction, has also been developed and its use as a chemical footprinting method 
is currently being investigated.  To date, there have been no known structural studies of 
either the NAT or SPV mRNA secondary elements, only computational structure predictions 
using mfold.54,55     
 The goal of this research was to use chemical and enzymatic footprinting methods to 
study the secondary structure of both the native and splice variant forms of human 
preproinsulin mRNA.  With this knowledge, these techniques could then be used to identify 
functional small molecule-RNA interactions.  The hypothesis, based upon the previous work 
on the ferritin IRE system, was that a small molecule that has an effect on the secondary 
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structure of the human proinsulin mRNA would be able to modulate proinsulin translation in 
vitro. 
 
3.3 Experimental 
3.3.1 Materials 
 Proteinase K (20 mg / ml), phenol/chloroform, acid phenol/chloroform, linear 
acrylamide, DEPC-treated water, Superase·In RNase inhibitor (20 U / µl), T7 RNA 
Polymerase PlusTM (200 U / µl), RNase A (1 µg / ml), RNase T1 (1 U / µl), RNase I (100 U / 
µl), alkaline hydrolysis buffer, TURBO DNase I, Gel Loading Buffer II, MEGAshortscriptTM 
T7 Kit,  MEGAscriptTM T7 Kit and MEGAclearTM transcription reaction purification kit were 
purchased from Applied Biosystems..  Promazine HCl, carbenicillin disodium salt, 
yohimbine HCl, dithiothreitol (DTT), neomycin B trisulfate hydrate, kanamycin B sulfate, 
hygromycin B, and Hoechst 33258 were purchased from Sigma-Aldrich.  Calf Intestinal 
Phosphatase (CIP), T4 DNA ligase and mini Quick Spin RNA Columns were purchased from 
Roche.  All restriction enzymes, T4 polynucleotide kinase, Klenow, T4 RNA ligase, and 
corresponding buffers were purchased from New England Biolabs.  Wheat germ extract and 
Rabbit Reticulocyte Lysate were purchased from Promega.  ChargeSwitch® PCR Clean-up 
Kit, Novex® Tricine-SDS running buffer, DryEase® Mini-Gel Drying Kit and Novex® 
Tricine Gels were purchased from Invitrogen.  [5’-32P]pCp (0.01 mCi/µl) and Easy Tag 
EXPRESS-[35S] Protein Labeling Mix (0.011 mCi / µl) were purchased from Perkin Elmer.  
Ultrafree-MC centrifugal filter devices were purchased from Millipore.  Plasmid purification 
Maxi- and Miniprep kits were purchased from Qiagen.  XL10-Gold® ultracompetent cells, 
QuickChangeTM II XL Site-Directed Mutagenesis Kit, pBluescript II SK(-), Herculase® II 
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Fusion DNA Polymerase, and PfuUltra® High-Fidelity DNA polymerase were purchased 
from Stratagene.  Reliant® FastLane® Pre-cast agarose gels, SeaPlaque® low-melting agarose 
and NuSieve® GTG® agarose were purchased from Lonza.  Polyspring glass inserts used in 
the flash-quench procedure were purchased from National Scientific.  PCR primers were 
purchased from the Nucleic Acid Core Facility at the UNC Lineburger Comprehensive 
Cancer Center.  The pBR328 vector containing the full-length human insulin cDNA clone 
(510 bases) was a gift from Dr. Graeme I. Bell of the University of Chicago. 
3.3.2 Methods 
3.3.2.1 Cloning of the Full-length Human Preproinsulin Splice Variant (FL-SPV) 
 Creation of full-length human preproinsulin cDNA using PCR:  The primers used in 
this study are listed in Table 3.1 (Primers 1-6).  A schematic representation of the constructs 
created is shown in Figure 3.4.  The plasmid received from G. I. Bell (referred to here as 
hINS plasmid) contained the full length human insulin cDNA sequence and was used as the 
DNA template during round 1 of PCR.  In order to produce a DNA template for transcription 
of the human preproinsulin splice variant sequence (SPV) PCR was used to add 74 bases of 
the 5’UTR sequence on the 5’ end of the human insulin cDNA sequence to form full-length 
SPV DNA.  After creation of the SPV DNA template, BamH I and EcoR I restriction sites 
were added to the 5’ and 3’ ends of the sequence during PCR amplification to facilitate 
cloning into the pBluescript II SK(-) vector (Primers 5c and 6).  The PCR conditions used for 
each round of amplification are found in Table 3.2, and generally follow the procedures 
provided by Stratagene for the respective polymerases.  During the first round of 
amplification 7.2 ng of the hINS plasmid was used as a DNA template.  After each round of 
amplification, the resulting products were visualized on a 3% NuSieve® GTG® agarose gel, 
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and gel plugs containing the desired PCR product were used as the template for future 
rounds.  Products from the final round of amplification were purified using a ChargeSwitch® 
PCR Clean-up Kit then used as a template for cloning.   
Cloning procedure:  Primers (600 pmol) used for round 5c of amplification (Primers 
5c and 6) were phosphorylated with T4 PNK (15 U; in 1X PNK Buffer, pH 9.0, 50 mM DTT, 
0.6 mM rATP) at 37°C for 45 min, followed by heat inactivation at 70°C for 10 min.  
Phosphorylated primers were used in a PCR reaction (50 µl; containing 1X Herculase® II 
reaction buffer, 200 µM each dNTP, 250 pmol each forward and reverse phosphorylated 
primer, 18-36 ng purified DNA template, 1 µl DMSO (100 %), 0.5 µL Herculase® II fusion 
DNA polymerase; denaturation at 98°C, 20 sec; annealing 65°C, 20 sec; and elongation 
72°C, 90 sec; 25 cycles).  After first trying to clone the full-length SPV sequence into 
pBluescript II SK (-) with the EcoR I and BamH I sites was unsuccessful, Sma I digestion of 
the vector was used to facilitate cloning through blunt-end ligation.  pBluescript II SK (-) 
vector (1.5 µg) was digested with 20 U Sma I (30 µl; 1X NEB buffer #4) at 25°C for 2 h.  
Complete digestion of the plasmid was verified using a 1% Reliant® FastLane® agarose gel 
(1X TBE for 30 min at 175 V).  The digested vector was then purified using 
phenol/chloroform extraction followed by ethanol precipitation, and brought up in 7 µl sterile 
water.  Digested vector (7 µl) was then dephosphorylated using calf intestinal phosphatase 
(CIP) (10 µl; containing 1X CIP buffer, 2 U CIP) at 37°C for 45 min.  The resulting product 
was purified on a 1% SeaPlaque® low-melting agarose gel (in 1X TBE) at 100 V.  The band 
containing the dephosphorylated, digested vector was excised from the gel after visualization 
using UV light.  To facilite the ligation of the digested vector with the phosphorylated PCR 
product, the agarose containing vector DNA was heated in a microcentrifuge tube to 65°C 
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and added to the ligation reaction before addition of T4 DNA ligase (11 µl; consisting of 4.0 
µl agarose containing vector DNA, 5.0 µl phosphorylated insert PCR product, in 1X T4 
DNA ligase buffer, 400 U T4 DNA ligase).  After incubation at 4°C overnight, the ligation 
reaction was melted at 68°C for 10 min, then diluted with 40 µl 1X TE, and the ligation 
incubated at 37°C until needed for the transformation.  The construct was transformed into 
XL-10 Gold® ultracompetent cells and plated on LB/carbenicillin plates overnight.  The 
orientation and sequence of all constructs were verified by sequencing.  This plasmid is 
referred to in this work as FL-SPV plasmid.    
3.3.2.2 Cloning of the 5’UTR of Human Preproinsulin Splice Variant (SPV-HP) 
 Creation of the human preproinsulin intermediate splice variant hairpin template 
(INT-SPV-HP) using PCR:  Primers used in this procedure are listed in Table 3.1 (Primers 5c 
and 9).  A schematic representation of the construct is seen in Figure 3.4.  SPV plasmid 
containing the full-length human preproinsulin splice variant sequence (FL-SPV) was used as 
a template.  PCR was used to amplify out the 5’UTR sequence and add an Xba I restriction 
site on the 3’ end to facilitate cloning and in vitro transcription.  Primers were 
phosphorylated using T4 polynucleotide kinase (as described in Section 3.3.2.1), and used in 
the amplification reaction with Herculase® DNA polymerase (50 µl; containing 1X 
Herculase® reaction buffer, 200 µM each dNTP, 400 pmol each forward and reverse primer, 
2.6 ng FL-SPV plasmid as a template, 1 µl DMSO (100%), 0.5 µl Herculase® II fusion DNA 
polymerase; 5 cycles of denaturation at 98°C, 20 sec; annealing 60°C, 20 sec; extension 
72°C, 30 sec, followed by 25 cycles of denaturation at 98°C, 20 sec; annealing 63°C, 20 sec; 
extension 72°C, 30 sec) as suggested by Stratagene.  The size of the resulting PCR products 
(referred to here as intermediate SPV hairpin PCR products) was checked on a Reliant® 
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FastLane® precast 2.5 % agarose gel.  To remove the remaining SPV parent plasmid in the 
PCR product, digestion with Dpn I was done using the protocol from the Stratagene 
QuickChangeTM II XL Site Directed Mutagenesis Kit.  The resulting solution was cleaned 
using a ChargeSwitch® PCR Clean-up Kit.  pBluescript II SK(-) vector was digested with 
EcoR I/Xba I or Sma I (as described in Section 3.3.2.1), and then dephosphorylated using 
calf intestinal phosphatase (as previously described).  Digested pBluescript II SK(-) vector 
and intermediate SPV hairpin PCR product were purified on a 1% SeaPlaque® low-melting 
agarose gel, and ligated together using T4 RNA ligase at 4oC overnight (as described 
previously).  The construct (INT-SPV-HP) was transformed into XL-10 Gold® 
ultracompetent cells according to the protocol provided by Stratagene, and plated on 
LB/carbenicillin plates overnight.  The orientation and sequence of all constructs were 
verified by sequencing. 
 Construction of the plasmid containing the human preproinsulin splice variant 
hairpin sequence (SPV-HP):  To remove extra base pairs between the T7 promoter and the 
start of the human preproinsulin 5’UTR sequence, the previously cloned plasmid (INT-SPV-
HP) was digested with Pst I (100 µl; containing 31.5 µg INT-SPV-HP plasmid, 1X NEB 
Buffer #3, 0.1 µg BSA, 200 U Pst I) for 2 h at 37°C, the purified by phenol/chloroform 
extraction and ethanol precipitation.  The resulting plasmid was brought up in 10 µl sterile 
water.  The Pst I digested plasmid was then digested with Kpn I (100 µl; containing 10 µl Pst 
I digested plasmid, 1X NEB Buffer #1, 0.1 µg BSA, 100 U Kpn I) for 2 h at 37°C.  The 
digested plasmid was then purified by phenol/chloroform extraction, and ethanol 
precipitation.  The digested plasmid was brought up in 10 µl sterile water.  After digestion, 
the remaining 3’ overhang sequence was removed with Klenow (50 µl; containing 1X NEB 
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buffer #2, 40 µM each dNTP, 20 U Klenow) by incubation for 15 min at 25°C.  The reaction 
was stopped by adding 1 µl  0.5 M EDTA and heating to 70°C for 20 min.  The plasmid was 
re-ligated, transformed into XL-10 Gold® ultracompetent cells, and the sequence verified.  
The resulting plasmid contained the preproinsulin 5’UTR with 19 bases between the T7 
promoter and the start of the UTR.  The folding of this construct was checked with mfold63,64 
and RNAstructure65 and was shown to have the same secondary structure as the original SPV 
hairpin RNA.  This structure is referred to in this work as SPV-HP.   
3.3.2.3 Creation of the Full-length and 5’UTR Native Human Preproinsulin  
Constructs (FL-NAT and NAT-HP) 
 Loop-out mutagenesis using a Stratagene QuickChangeTM II XL Site Directed 
Mutagenesis Kit was performed on the FL-SPV and SPV-HP plasmids to remove the 26 
bases present in the SPV hairpin RNA that are not present in the native preproinsulin (NAT, 
and NAT Hairpin) RNAs.  Primers were constructed so that the deletion fell in the middle of 
the sequence and are listed in Table 3.1 (Primers 7 and 8).  A schematic representation of the 
construct is seen in Figure 3.4.  PCR amplification was performed using PfuUltra® DNA 
polymerase, and the methylated parental DNA template was degraded using Dpn I.  The 
mutants were transformed into XL-10 Gold® ultracompetent cells.  DNA was sequenced, 
cells were grown up, and plasmids purified using a Maxi-prep kit.  The resulting plasmids 
contained the sequences for either the full-length native human preproinsulin mRNA, or the 
native hairpin RNA sequence.  These plasmids are referred to in this work as FL-NAT and 
NAT-HP, respectively.    
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3.3.2.4 Transcription of NAT and SPV Hairpin RNA 
   Plasmid containing the desired sequence was digested with Xba I (100 µl; 
containing  ~ 100 µg plasmid (NAT-HP or SPV-HP), 1X NEB Buffer #2, 0.1 µg BSA, 200 U 
Xba I) for 2 h at 37°C , treated with 0.5% SDS and 10 µg proteinase K for 2 h at 50°C, and 
then purified by phenol/chloroform extraction and ethanol precipitation.  The concentration 
of the digested plasmid was determined by taking the absorbance at 260 nm, and purity was 
assessed by using the A260/A280 ratio.  To generate hairpin RNA a MEGAshortscriptTM T7 
Kit was used according the protocol provided by Applied Biosystems for 4 h, with the 
addition of high concentration T7 RNA polymerase (200 U T7 Polymerase PlusTM ) to 
increase yields, and 20 U Superase·In to inhibit RNase degradation.  DNA in the resulting 
sample was digested using 30 U TURBO DNase provided with the MEGAshortscriptTM Kit 
at 37oC for 15 min.   Production of the RNA transcript was verified on a 10% denaturing (8 
M Urea) polyacrylamide gel.  The RNA was purified using a mini Quick Spin RNA Column 
(following the protocol provided by Roche), followed by acid phenol/chloroform extraction, 
and ethanol precipitation.  Absorbance at 260 nm was used to determine the final RNA 
concentration.   
3.3.2.5 RNA End-labeling     
 RNA was 3’ end labeled with 50 µCi [5’-32P]pCp using T4 RNA ligase (30 µl; 
containing 1X T4 RNA ligase buffer, ~150 µM RNA template, 30 U Superase·In, 3 µl 
DMSO (100%), 60 U T4 RNA ligase) overnight at 4oC.  RNA was run through a mini Quick 
Spin RNA column (following the protocol provided by Roche) and further purified on a 
small 8 % (7 M Urea) polyacrylamide gel for 30 min at 200 V.  RNA bands were visualized 
by autoradiography and excised from the gel.  Gel slices were crushed and soaked in elution 
  101
buffer (0.5 M NH4OAc, 1 mM EDTA, 0.1% SDS) with 20 U Superase·In RNase inhibitor in 
Utrafree-MC filters at 37oC overnight.  Samples were spun down at 4,000 x g for 15 min then 
ethanol precipitated overnight with 5 µg linear acrylamide.  RNA concentration was 
determined using the absorbance at 260 nm. 
3.3.2.6 RNase Cleavage Assay 
 Footprinting solutions were made by adding a trace amount (~ 0.53 µM) of 
radiolabeled NAT-HP or SPV-HP RNA to a stock solution (130 µl; containing 3.9 µM 
unlabeled RNA, in 80 mM Tris / 20 mM KCl, pH 7.4).  The RNA solution was then folded 
by heating to 95oC for 5 min followed by slow cooling to room temperature.  Aliquots of the 
stock solution (5 µl) were used in the RNase cleavage reactions.  To determine the correct 
concentration of RNase for single hit kinetics, the footprinting solutions (10 µl; containing 1 
µl RNase, 4 µl ddH2O) were then incubated for 20 min at room temperature.  Varying 
concentrations of RNase A (0.00001 - 0.001 pg) and RNase T1 (.001 - 1 U) were used, and 
the reaction stopped by adding 10 µl Gel Loading Buffer II.  Samples were separated on 10% 
(7 M urea) denaturing polyacrylamide gels, exposed to a phosphorimaging screen overnight 
and analyzed using a Storm® 860 phosphoimager.   
Once the correct concentrations of RNase were determined, footprinting reactions 
were performed to determine the small molecule binding site.  RNA was folded as described 
above, and footprinting solutions were incubated with varying concentrations of the small 
molecule for 20 min at room temperature.  RNase A (0.0001 U, 10 min, or 0.001 U, 5 min) 
and RNase T1 (0.2 U, 10 min) were added and incubated for the indicated time.  The 
cleavage reaction was stopped by adding 10 µl Gel Loading Buffer II.  Samples were 
separated on 10% (7 M urea) denaturing polyacrylamide gels, exposed to a phosphorimaging 
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screen overnight and analyzed using a Storm® 860 phosphoimager.  Band intensity was 
quantified using ImageQuant® software.  RNA ladders were constructed using the 3’ labeled 
RNA via enzymatic cleavage by RNase T1, and alkaline hydrolysis using protocols from 
Applied Biosystems.  
3.3.2.7 RuO2+ Small Molecule Binding Assay 
 The RuO2+ oxidant was generated from Ru-OH2 by bulk electrolysis, holding the 
aqueous solution at 0.85 V with rapid stirring for 10 min.66,67  Generation of RuO2+ was 
visually evident through a color change from brown to yellow, and by leveling off of the 
current.  Concentration of RuO2+ was determined by the absorbance of Ru-OH2 at 476 nm (ε 
= 9600 M-1cm-1).  The Ru-OH2 complex was generated by reduction of RuO2+ with an excess 
of L-ascorbic acid.  A stock solution  of  32P 3’ end labeled RNA (~1.5 µM) was folded in 40 
mM Tris/ 10 mM KCl (pH = 7.4) by heating to 95oC for 5 min followed by slow cooling to 
room temperature.  Aliquots of folded, labeled RNA solution (5 µl, ~0,75 µM labeled RNA ) 
were used in each reaction.  Labeled RNA solution (5 µl) and drug were incubated at room 
temperature for 20 min (reaction volume 7 µl).  Concurrently, RuO2+ was generated as 
described above.  RuO2+ (100 µM) was then added and reacted with the folded RNA solution 
for 5 min at room temperature (10 µl total reaction volume).  The reaction was quenched 
with 15 µl ethanol, and speed vacuumed to dryness.  Lyophilized RNA was then aniline 
treated with 20 µl 1 M aniline-acetate (pH 4.5), in the dark for 20 min at 60oC.  The solution 
was frozen to -80oC, lyophilized to remove the aniline, then washed with water, frozen, and 
lyophilized two more times.  Samples were resuspended in 5 µl Gel Loading Buffer II, 
separated on 10 % (7 M urea) denaturing polyacrylamide gels, exposed to a phosphorimaging 
screen overnight and analyzed using a Storm® 860 phosphoimager.  Band intensity was 
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quantified using ImageQuant® software.  RNA ladders were constructed using 3’ labeled 
RNA via enzymatic cleavage by RNase T1, and alkaline hydrolysis using protocols from 
Applied Biosystems.  
3.3.2.8 Flash-Quench Oxidation 
 A stock solution of 32P-pCp 3’ end labeled RNA (~4.5 µM) was folded in 40 mM 
Tris-Cl (pH = 7.6) by heating to 95oC for 5 min followed by slow cooling to room 
temperature.  Aliquots of 5 µl labeled RNA solution (~0.5 µM labeled RNA) and drug were 
incubated in glass polyspring inserts at room temperature for 20 min.  After incubation, 100 
µM Ru(bpy)32+ and 1 mM Co(NH3)5Cl2+ were added to the RNA (total reaction volume 20 
µl) and the solutions were kept in the dark to prevent photolysis.  The flash-quench 
method68,69 was then used to generate oxidative lesions on the RNA using Ru(bpy)33+ as an 
electron donor, and Co(NH3)5Cl2+ as a quencher.  Photolysis was performed with a 350 W 
Hg lamp (Oriel) with a 265 nm cutoff filter, and water filter, for 10 min.  The reaction was 
quenched with 60 µl ethanol, and then ethanol precipitated with 2.5 µg linear acrylamide and 
0.5 µl glycoblue, followed by treatment with aniline (see Section 3.3.2.7).  The samples were 
resuspended in 5 µl Gel Loading Buffer II, and separated using a 10% (7 M urea) denaturing 
polyacrylamide gel, exposed to a phosphorimaging screen overnight and analyzed using a 
Storm® 860 phosphoimager.  Band intensity was quantified using ImageQuant® software.  
RNA ladders were constructed using the 3’ labeled RNA via enzymatic cleavage by RNase 
T1, and alkaline hydrolysis using protocols from Applied Biosystems.            
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  3.3.2.9 Transcription of Full-length mRNA: Human NAT Preproinsulin and Human 
SPV Preproinsulin 
 The human preproinsulin plasmids FL-NAT and FL-SPV encode for the 
preproinsulin mRNA with the native (NAT, 59 bases) or splice variant (SPV, 85 bases) 
sequence in the 5’UTR, in the pBluescript II SK(-) vector under the T7 promoter, 
respectively.  The plasmids were digested with BamH I (100 µl ; containing ~100 µg plasmid 
in 1X BamH I buffer, 0.1 µg BSA, 200 U BamH I) at 37°C for 2 h.   All digestions were 
followed by treatment with 0.5 % SDS, 10 µg proteinase K for 2 h at 50°C, and purification 
using phenol/chloroform extraction and ethanol precipitation.   Concentration of linearized 
vector was determined using the absorbance at 260 nm.  Full length human preproinsulin 
mRNA was transcribed from the linearized vector using the T7 promoter.  All transcriptions 
were performed using a MEGAscript T7 KitTM for 3 h at 37°C (following the protocol 
provided by Applied Biosystems) with addition of 20 U Superase·In to inhibit RNA 
degredation.  Excess plasmid DNA was removed by incubation with TURBO DNase (40 U, 
15 min at 37°C) followed by purification using a MEGAclear KitTM (according to the 
protocol provided by Applied Biosystems), acid phenol/chloroform extraction, and ethanol 
precipitation.  Production of the correct size mRNA was confirmed by electrophoresis on a 
Reliant® FastLane® 1.25% agarose RNA gel.  RNA concentrations were determined using 
the absorbance at 260 nm.     
3.3.2.10 In Vitro Translation of mRNA 
 Translation of mRNA (NAT / SPV, 1.5 µg; luciferase 1 µg; total reaction volume 25 
µl) occurred after pre-incubation with or without small molecule for 20 min at 30oC using 
wheat germ extract and 11 µCi [35S]methionine (following the procedure provided by 
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Promega) for 60 min at 25°C.  Synthesized protein was analyzed by electrophoresis on either 
10-20% or 16% Tricine gels in Novex® Tricine-SDS running buffer (pH 8.3) according to the 
protocol provided by Invitrogen.  The gels were fixed in a 50% methanol / 10% acetic acid 
solution for 10 min, rinsed twice with ddH2O, dried using a DryEase® Mini-Gel Drying Kit 
and exposed to a phosphorimaging screen overnight.  Protein band intensities were 
quantitated based on [35S]methionine incorporation using ImageQuant® software.      
 
3.4 Results and Discussion 
3.4.1 Secondary Structure Analysis of 32P-End-Labeled Human Preproinsulin Hairpin RNA 
 The 5’UTR of the human preproinsulin gene contains exon 1 and part of exon 2, 
which are separated by intron 1 in the unspliced RNA.  Any changes in intron 1 will alter the 
5’UTR without disrupting the gene product.  Chemical and enzymatic footprinting were used 
to investigate the secondary structure of the native and splice variant forms of the human 
preproinsulin hairpin RNA.  Experiments were carried out under conditions that should 
produce one cleavage or modification per RNA molecules.  RNAs used for the nuclease 
mapping contained 59 bases of the 5’UTR for the native insulin construct, and 85 bases for 
the splice variant construct, as well as flanking sequence.  The results of the footprinting 
agreed with the proposed secondary structures (Figure 3.3) and are summarized in Figure 
3.5.  
3.4.1.1 Native Preproinsulin mRNA Structure 
For the native construct, most nucleotides predicted to be in single-stranded regions 
(loops or bulges) were cleaved with RNase A, T1 or I (Figure 3.6).  Some variability in 
cleavage is seen in positions surrounding loop/bulge regions indicating possible nucleotide 
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flexibility.  An example of this variability is seen in the cleavage with RNase T1 and RNase I 
around the G49 position.  This nucleotide is computationally predicted to be double stranded, 
but is cleaved at all relevant nuclease concentrations.  Cleavage by RNase V1, which is used 
in the identification of double stranded regions, also occurs around this position, suggesting 
that there may be flexibility in the RNA structure at this position in solution.  Chemical 
footprinting with RuO2+, which causes oxidation of solvent-accessible guanines prone to 
cation binding, produces a cleavage pattern similar to the RNase T1 pattern (Figure 3.7).  
Prominent cleavage occurred at positions G25, G28, G30 and G31 all found in the terminal 
loop region.  Due to the solvent accessibility of the unpaired bases in this region, cleavage 
with RuO2+ also appeared to occur at nucleotides surrounding the guanines, though this could 
be an artifact of separation by electrophoresis.  Use of the flash-quench technique with 
Ru(bpy)32+ also causes oxidation of guanine nucleobases.  Prominent cleavage occurred at 
the same positions as found using RuO2+, along with secondary cleavage seen at G15, G16, 
G39, G42 and G49 (Figure 3.8).  Due to the short lifetime of the excited Ru(bpy)33+ oxidant, 
cleavage occurs in a static manner, at regions that are spatially near the oxidant, not those 
that are able to “breathe” and become solvent accessible over a longer timescale.  Cleavage at 
G39, which was not seen with either RNase T1 or RuO2+, suggests that this position may not 
be flexible enough to be in direct contact with either RuO2+ or the RNases, but oxidation of 
the guanine may occur through long range electron transfer with Ru(bpy)33+.           
Double-stranded stem regions were probed using RNase V1.  Cleavage patterns were 
similar to those predicted computationally.  The region around G49 in the lower stem region 
produced an area of cleavage overlap with RNase T1, indicating that this lower stem region 
may be structurally flexible. 
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A preproinsulin binding factor (ppIGE regulatory factor) has been identified that 
binds in the area 40-48 nucleotides from the beginning of the 5’UTR and is involved in 
glucose-regulated translational control.37  From the predicted secondary structure, this 
sequence spans a region which includes a four nucleotide bulge, 5’-A43U44C45A46-3’, flanked 
by base paired nucleotides.  This bulged region could be important for making contacts with 
the ppIGE regulatory factor, similar to what is seen in the IRP:IRE system.  Mutation of this 
sequence, or disruption as seen in the splice variant, abolishes this glucose-regulated 
translational control.     
3.4.1.2 Preproinsulin mRNA Splice Variant Structure 
 The preproinsulin splice variant contains an extra 26 bases than the native hairpin 
RNA that change the overall secondary RNA structure.  Because the inserted sequence is in 
the middle of the hairpin, the ends of the two constructs share a similar structure.  This can be 
seen in both the predicted secondary structure and the resulting cleavage patterns of the 
native and splice variant constructs (Figures 3.3 and 3.5).   
Overall, the predicted secondary structure of the splice variant differed slightly from 
the cleavage pattern seen using enzymatic and chemical nucleases (Figures 3.5 and 3.9).  
Little cleavage was seen around nucleotides 44-45 and 54 which were predicted to be single 
stranded.  There was no evidence of base pairing occurring in this region, as evidenced by the 
lack of substantial cleavage by RNase V1.  Also, the area around G75 which is found in the 
lower stem region is cleaved by RNase T1, suggesting that this is a more flexible region that 
exhibits base paired characteristics.  The other RNase cleavage patterns agree with the 
predicted structure.   
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 The RuO2+ and flash-quench cleavage patterns are similar to that of RNase T1 
(Figures 3.10 and 3.11).  Prominent cleavage is seen at positions: G10, G11, G19, G25, 
G28, G39, G42, G43, G47, G54, G55, G62, and G64 in both methods.  Due to the size of the 
preproinsulin SPV hairpin RNA, it was difficult to get single nucleotide resolution using gel 
electrophoresis.  The structure of a population of folded molecules can vary in solution.  It is 
possible that there is a greater tertiary structure present in the preproinsulin hairpin RNA that 
accounts for some of the reduced cleavage in single stranded regions.  These interactions 
would not be predicted using computational secondary structure methods.  This could also 
explain some of the regions such as those around G75 which show both single and double 
stranded characteristics.  Once the secondary structures of the preproinsulin mRNAs were 
probed, this information was used in the search for small molecules that bind preproinsulin 
hairpin RNA.                 
3.4.2 Screening Compounds to Find a Human Preproinsulin Hairpin RNA Binder 
 To determine if our hypothesis was valid, a number of drug-like molecules were 
screened for binding to both preproinsulin hairpin RNA constructs.  The structures of these 
molecules are given in Table 3.3.  There are three classes of compounds that are well-known 
for their interactions with nucleic acids.70  These include intercalating agents (i.e. ethidium 
bromide), minor groove binders (i.e. Hoechst dyes), and major groove binders (i.e. methyl 
green).  Due to the absence of previous work on these RNAs, and little information about 
their secondary and tertiary structures, we began our investigation by screening compounds 
that were known RNA binders.  Initially, yohimbine and promazine, the two compounds that 
were able to up-regulate ferritin synthesis (discussed in Chapter 2), were studied for their 
ability to bind and regulate translation of preproinsulin mRNA.  After this initial screen, four 
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more compounds were tested for their binding ability.  Overall the compounds fell into four 
categories: 1) phenothiazine derivatives,71,72 2) Hoechst dyes,73 3) indole derivatives,71 and 4) 
aminoglycoside antibiotics.59,60   
 Compounds were screened against the native or splice variant sequence using RNase 
footprinting, the flash-quench technique or the RuO2+ footprinting assay.  Promising 
candidates were determined to be those that inhibited RNA cleavage or guanine oxidation, or 
caused a change in the secondary structure of the RNA.  Promazine and yohimbine showed 
no evidence of binding to either RNA (Figures 3.12 and 3.13).  A secondary screen 
identified neomycin B (Figures 3.14-3.21) and kanamycin B (Figures 3.22-3.29) as 
promising compounds for both constructs, while Hoechst 33258 (Figures 3.14 and 3.30) and  
hygromyin B (Figures 3.31 and 3.32) lacked any specific binding characteristics for either 
RNA, and were not further studied.  Increasing concentrations of neomycin B caused a 
decrease in cleavage around nucleotides 7-8, 13, 25-31, 42-47 and 49-50 of the NAT 
construct, and kanamycin B changed the amount of cleavage around nucleotides 7-8, 25-31, 
36-39 and 44-49 in the NAT construct.  For the SPV construct, changes in cleavage were 
seen around nucleotides 20-23, 30-31, 40, 42-43, 47, 50-51, 70-71, and 75 with neomycin B.  
Kanamycin B produced changes in cleavage at all nucleotides in the SPV construct.  Of the 
compounds tested, promazine, yohimbine, neomycin B and kanamycin B were studied more 
thoroughly.  There is some concern that these compounds exhibit non-specific binding due to 
their effect on cleavage in multiple regions of the SPV hairpin RNA, although this could be 
due to a change in the overall secondary structure.  Aminoglycosides such as neomycin B 
have been shown to interact with multiple RNAs; they are often called “promiscuous”, 
because they bind a range of different targets, and more than one aminoglycoside molecule 
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can bind per RNA.74-81  The majority of RNA binding compounds, including the 
aminoglycosides, are cationic compounds carrying several positively charged groups.  
Electrostatic interactions between the negatively charged RNA backbone and cationic groups 
enhance the binding affinity in RNA-drug complexes, contributing to both specific and 
nonspecific binding interactions.77  Despite all this, aminoglycosides have been shown to 
display high specificity in eliciting biological function by interaction with a particular RNA 
structure, such as the bacterial decoding site RNA.77        
3.4.3 Comparison of Methods Used to Identify a Human Preproinsulin Hairpin RNA Binder 
 Of the three methods used to identify small molecules that are able to bind to the 
hairpin RNA constructs, enzymatic cleavage using a combination of RNases was the most 
beneficial followed by the use of the RuO2+ assay.  RNase A is able to cleave after single-
stranded C and U nucleotides, while RNase T1 is able to cleave after single-stranded guanine 
nucleotides.  Using a combination of RNase A and RNase T1 allowed for more of the hairpin 
RNA structure to be probed versus the solvent-accessible guanine specific RuO2+ cleavage.  
The flash-quench reaction showed an interesting result; with increased small molecule 
concentration, the amount of RNA cleavage increased to such a degree that no full-length 
RNA remained (Figure 3.33).  The concentrations of small molecule used in this assay were 
the same as those used in the RuO2+ assay and the same ratio as those used in the RNase 
experiments.  The mechanism behind the enhanced cleavage is unknown, but it is possible 
that the aminoglycosides are enhancing the ability of the Ru(bpy)32+ molecule to be excited, 
either by direct electron transfer of the small molecule, or through interaction with the 
Co(NH3)5Cl2+ quencher.  This would cause an increased number of Ru(bpy)33+ molecules in 
the excited state, resulting in a larger amount of cleaved RNA.        
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3.4.4 Regulation of Protein Synthesis by Small Molecules: In Vitro Translation Assay 
3.4.4.1 Human Preproinsulin Native and Splice Variant mRNA Constructs 
 After determining that two small molecules, neomycin B and kanamycin B, bound or 
had an effect on the secondary structure of the preproinsulin native and splice variant 
hairpins, we sought to determine whether these small molecules could retain their binding 
characteristics in a more complex in vitro translation mixture.  Use of both the rabbit 
reticulocyte lysate and wheat germ cell-free expression systems was explored, and the wheat 
germ assay was superior to the reticulocyte lysate for production of preproinsulin.  To 
perform this assay, full length native or splice variant preproinsulin mRNA was pre-
equilbrated with or without small molecule before the extract, amino acid mixture and 
radiolabeled methionine were added.  A time course assay was performed to make sure 
preproinsulin synthesis rates were linearly dependent on incubation time at the time chosen 
(30 min). 
 Neomycin B and Kanamycin B showed an effective decrease in preproinsulin 
synthesis for both the native and splice variant forms at all concentrations tested (Figures 
3.34 and 3.35).  This result validated our hypothesis that a small molecule that has an effect 
on the secondary structure of the human preproinsulin mRNA should be able to modulate 
proinsulin translation.  The effect of promazine and yohimbine was also examined, but 
neither of these small molecules caused a change in the amount of translation (Figure 3.36).  
3.4.4.2 Wild-type Luciferase mRNA Construct 
 To determine if the results observed with the down-regulation of preproinsulin 
synthesis by neomycin B and kanamycin B were dependent on the identity of the transcript, 
mRNA encoding wild-type luciferase was used as a control.  A decrease in luciferase protein 
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translation was seen for both small molecules at increasing concentrations (Figure 3.37).  
Kanamycin B showed a greater reduction in protein synthesis than neomycin B, but both 
compounds had a profound affect on protein synthesis at concentrations greater than 10 µM.  
These results indicate that at high concentrations the aminoglycosides used here most likely 
have an effect on the translational machinery of the wheat germ system.  Aminoglycosides 
have shown some toxicity at high concentrations.  At concentrations lower than 10 µM, the 
effect of these small molecules on preproinsulin synthesis may be greater than the effect on 
the luciferase construct, but more data is needed to at lower concentrations to support this 
result.           
 Recently, the existence of a binding factor similar to the iron regulatory protein found 
in the ferritin system, was identified.37  It has been suggested that binding of this factor to the 
preproinsulin binding element prevents assembly of the translational initiation machinery and 
blocks preproinsulin protein synthesis.  Glucose is thought to interfere with the binding of the 
regulatory factor, stimulating preproinsulin synthesis.  Because the presence of this factor is 
limited to the extracts of islet cells, these experiments should be repeated in human islet 
extract or in vivo in human islets to determine the ability of the aminoglycosides to interact 
with the RNA when the factor is present. 
 
3.5 Conclusions 
 Two main conclusions can be drawn from these experiments.  First, footprinting by 
enzymatic cleavage with RNases, or chemical cleavage with RuO2+ are better methods for 
determining the specific binding sites for small molecules on mRNA, than the flash-quench 
technique.  Together, the RuO2+ and RNase cleavage methods provide a valuable screen for 
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binding site identification.  However, with these techniques it would be difficult to elucidate 
binding sites with nucleotide resolution on RNA targets larger than the preproinsulin splice 
variant used here.  Second, differential binding of small molecules to specific three-
dimensional structures in mRNA can alter mRNA translation.  As seen with other 
aminoglycoside:RNA interactions, this binding causes the down-regulation of protein 
synthesis.82,83  A future goal of this work is to identify a small molecule would be able to 
enhance preproinsulin biosynthesis, allowing more protein to be stored in the secretory 
granules for release upon glucose stimulus.     
 These studies indicate that neomycin B and kanamycin B bind secondary structures in 
both the native and splice variant preproinsulin mRNA.  Binding of these small molecules 
causes a conformational change in the secondary structure of the 5’UTR that result in the 
down-regulation of protein synthesis.  Identification of a small molecule that prevents 
interaction of the binding factor with the glucose regulation element in the native 
preproinsulin mRNA should allow for the up-regulation of preproinsulin synthesis.  
The alternative splicing of the human preproinsulin mRNA results in a higher level of 
translation than is observed for the normally spliced RNA.54  The splice variant form of 
preproinsulin mRNA is stimulated after long term (>24 h) exposure to glucose, indicating its 
expression may be important in those suffering from hyperglycemia due to insulin resistance 
or reduced insulin secretion.  Because the splice variant disrupts the glucose factor binding 
site, finding a small molecule that selectively binds to this splice variant form should allow 
an increased pool of preproinsulin to be synthesized.  This would help maintain insulin stores 
in times of increased insulin secretion.     
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3.6 Future Directions 
Insulin synthesis and secretion from pancreatic β-cells is a complex biological 
process regulated at many levels.  More work on the drug discovery aspect of this project is 
needed to increase the selectivity of the small molecules for the different preproinsulin forms.  
With the identification of a glucose regulatory element in the native preproinsulin mRNA, 
identification of small molecules that bind specifically and selectively in this region should 
prevent ppIGE regulatory factor binding and allow for the up-regulation of preproinsulin 
synthesis. 
  More work could also be done to determine the effect of the ppIGE regulatory 
factor:ppIGE interaction.  The glucose binding element is thought to act solely through its 
primary sequence.54  It is hypothesized that binding of this factor acts in a manner similar to 
that of the IRP:IRE interaction, by preventing translation initiation machinery assembly, 
resulting in decreased protein synthesis.54  Another possible effect would be that binding of 
the glucose binding factor would create a “landing pad” for ribosomes, stimulating the 
production of preproinsulin.  Use of siRNA, peptides, or other molecules that are able to 
target specific sequences should also be investigated.  Insulin production is also regulated at 
the transcriptional level, so small molecules that enhance the transcription of preproinsulin 
mRNA could have an effect on insulin secretion.  
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3.7 Tables 
Table 3.1 Oligonucleotides used in human preproinsulin cloning.  Lowercase letters 
represent nucleotides involved in the restriction site sequence.  
Sequence (5’ to 3’) Description Restriction 
Site 
1. TGC GTC AGA TCA CTG TCC TTC 
TGC CATGGC CCT GTG GAT 
 
2. TGT TCC AAG GGC CTT TGC GTC 
AGA TCA CTG TCC TTC TGC CAT 
 
3. AAG CAG GTC TGT TCC AAG GGC 
CTT TGC GTC AGA TC 
 
4a. GAG GCC ATC AAG CAG GTC TGT 
TCC AAG GCC 
 
4b. GCA TCA GAA GAG GCC ATC AAG 
CAG GTC TGT 
 
5a. GGA CAG GCT GCA TCA GAA GAG 
GCC ATC AAG C 
 
5b. AGC CCT CCA GGA CAG GCT GCA 
TCA GAA GAG G 
 
5c. cgaattc AGC CCT CCA GGA CAG GCT 
GCA TC  
 
6. gcggatcc TCT AGT TGC AGT AGT TCT 
CCA GCT GGT AGA GGG AGC 
 
7.  GGC CAT CAA GCA GAT CAC TGT 
CCT TCT GCC 
 
8. GGC AGA AGG ACA GTG ATC TGC 
TTG ATG GCC 
 
9. gctctaga GCC ATG GCA GAA GGA 
CAG TGA TCT GAC 
 
5’ primer for round 1 of 
amplification 
 
5’ primer for round 2 of 
amplification 
 
5’ primer for round 3 of 
amplification 
 
5’ primer for round 4a of 
amplification 
 
5’ primer for round 4b of 
amplification 
 
5’ primer for round 5a of 
amplification 
 
5’ primer for round 5b of 
amplification 
 
5’ primer for round 5c of 
amplification and SPV 
hairpin construction 
3’ primer for full length 
preproinsulin cloning 
 
5’ primer for NAT construct 
creation  
 
3’ primer for NAT construct 
creation 
 
3’ primer for making SPV 
hairpin construct 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EcoR I 
 
 
BamH I 
 
 
 
 
 
 
 
 
Xba I 
 
  116
Table 3.2. PCR Conditions used in human preproinsulin cloning.  
 
PCR Conditions Round of 
Amplification Reaction Conditions Segment Number of Cycles 
Temperature  
(°C) Time  
1 1 95 2.5 min 
95 1 min 
58 1 min 2 30 
72 1 min 
1 
3 1 72 5 min 
1 1 95 2.5 min 
95 1 min 
60 1 min 2 5 
72 1 min 
95 1 min 
65 1 min 3 25 
72 1 min 
2 
4 1 72 5 min 
3 1-4 Same as Round 2 
1 1 95 2.5 min 
95 1 min 
54 1 min 2 5 
72 1 min 
95 1 min 
65 1 min 3 25 
72 1 min 
4a 
4 1 72 5 min 
4b 1-4 Same as  Round 4a 
1 1 95 2.5 min 
95 1 min 
58 1 min 2 5 
72 1 min 
4c 
- 50 µl reaction volume 
- 1X PFU Ultra® Buffer 
- 400 pM each forward 
and reverse primers 
- 200 µM each dNTP 
- 0.5 µl PFU Ultra® 
Polymerase 
 
 
3-4 Same as Round 4a 
1 1 98 2 min 
98 20 sec 
55 20 sec 2 5 
72 30 sec 
98 20 sec 
65 20 sec 3 25 
72 30 sec 
5a 
4 1 72 3 min 
1 1 98 2 min 
98 20 sec 
57 20 sec 2 5 
72 30 sec 
5b 
3-4 Same as Round 5a 
1 1 98 2 min 
98 20 sec 
60 20 sec 2 5 
72 30 sec 
5c 
- 50 µl reaction volume 
- 1X Herculase® Buffer 
- 250 pM each forward 
and reverse primers 
- 200 µM each dNTP 
- 1 µl DMSO (100 %)  
- 0.5 µl Herculase® II 
fusion DNA 
polymerase 
 
3-4 Same as Round 5a 
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Table 3.3. Names and basic structures of compounds tested in the preproinsulin binding 
assay. 
Compound Name Structure 
Yohimbine 
 
Promazine 
 
Hoechst 33258 
 
Hygromycin B 
 
Neomycin B 
 
Kanamycin B 
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3.8 Figures 
 
Figure 3.1. Schematic of the human insulin sequence and secondary structure.  Disulfide 
bonds (shown here as black lines), are formed between the A- and B-chain at residues 
A7/B7, and A20/B19.  The A-chain contains an internal disulfide bond, between residues 6 
and 11.      
Preproinsulin 
Proinsulin 
Mature insulin 
Signal 
sequence 
B-chain
C-peptideA-chain 
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Figure 3.2.  Human insulin biosynthesis.  Insulin is initally synthesized as preproinsulin in 
the rough endoplasmic reticulum (RER).  Removal of the signal peptide produces proinsulin.  
Proinsulin is transferred from the RER, through the golgi, and is deposited into secretory 
granules.  Mature insulin is formed in these granules through removal of of the C-peptide by 
the prohormone convertases (PC) 1/3 and 2, and by carboxypeptidase E/H.  Adapted from a 
figure by Issac Yonemoto.     
Cytosol
ER 
Lumen
Golgi
Secretory 
Vesicle 
Ribosome 
Signal peptide
B-chain
C-peptide
A-chain 
Disulfide 
bond
Preproinsulin 
Proinsulin
Mature insulin
Protease 
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Figure 3.3. Proposed secondary structures of the 5’UTRs of the human preproinsulin 
mRNA.   The native human preproinsulin 5’UTR (A) and the human preproinsulin splice 
variant 5’UTR (B) predicted by mfold.63,64  The calculated energies (∆G) were -13.3 for the 
NAT and -24.5 for the SPV 5’UTR.  The arrows in (B) mark the 26 base intronic sequence 
present in the splice variant and the shaded area represents the preproinsulin mRNA glucose-
responsive translation element, or ppIGE.   
 
 
A B
NAT SPV
 C 
  C 
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Figure 3.4. Schematic representation of preproinsulin full-length mRNA and hairpin 
RNA constructs.  Schematic representation of (A) the hairpin RNA constructs and (B) the 
full length preproinsulin constructs.  Symbols: (+) indicates residues in the pBluescript SK (-
) vector; (-) represents the 5’UTR sequence shown in section C; (+1) refers to the 
transcription start site and the arrow represents the translation start site.  The underlined 
sequence in (C) is the splice variant sequence found in the FL-SPV and SPV-HP constructs.     
A 
B 
C 
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Figure 3.5. Comparison of guanine cleavage sites in the native and splice variant 
preproinsulin RNA hairpins.    
A B
NAT SPV
= RuO2+ cleavage 
= Flash-quench cleavage 
= RNase T1 cleavage 
C
   C 
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Figure 3.6. Analysis of the native preproinsulin mRNA hairpin structure using RNase 
cleavage.  All lanes, [RNA] ~5 µM.  Lane 1, folded RNA only.  Lane 2, alkaline hydrolysis 
ladder.  Lane 3, guanine Ladder.  Lanes 4-6, cytosine, uridine ladder.  [RNase], time: Lane 7, 
RNase A, 0.001 U, 5 min; Lane 8, RNase A, 0.001 U, 10 min; Lane 9, RNase T1, 1 U, 10 
min; Lane 10, RNase T1, 1 U, 15 min; Lane 11, RNase T1, 0.2 U, 5 min; Lane 12, RNase 
T1, 0.2 U, 10 min; Lane 13, RNase I, 0.1 U, 15 sec; Lane 14, RNase I, 0.01 U, 2 min; Lane 
15, RNase I, 0.01 U, 2.5 min; Lane 16, RNase I, 0.01 U, 1 min; Lane 17, RNase V1, 0.1 U, 
15 min; Lane 18, RNase V1, 0.2 U, 10 min; Lane 19, RNase V1, 0.2 U, 15 min.        
 
 
             1      3         4      6      8    10   12    13   15    17   19 
10/11 
22/23 
30 
25/28 Large ss 
bulge  
49 
36 
44/45 
ds region
ACUA ss 
bulge  
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Figure 3.7 Analysis of the native preproinsulin mRNA hairpin structure using 
Ru(tpy)(bpy)O2+ mediated guanine oxidation.  All lanes, [RNA] ~ 0.75 µM.  Lane 1, RNase 
T1, 0.2 U, 10 min.  Lane 2, RNase A, 0.001 U, 10 min.  Lane 3, RNase A, 0.001 U, 5 min.  
Lane 4, guanine ladder.  Lane 5, alkaline hydrolysis ladder.  Lanes 6-13, reaction time 5 min.  
[RuO2+]: Lane 6, 250 µM; Lane 7, 200 µM; Lane 8, 150 µM; Lane 9, 100 µM; Lane 10, 50 
µM; Lane 11, 25 µM. Lane 12, folded RNA with aniline treatment. Lane 13, folded RNA 
without aniline treatment. 
     1      3      5       7      9    11    13  
10-11 
28-31 
25 
    49 
22-23 
35-36 
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Figure 3.8 Analysis of the native preproinsulin mRNA hairpin structure using the flash-
quench technique.  Lanes 1-13, [RNA] ~ 1 µM.  Lane 1-5, controls: Lane 1, folded RNA 
with aniline treatment; Lane 2, no photolysis; Lane 3, Ru(bpy)32+ oxidant only; Lane 4, 
Co(NH3)5Cl2+ quencher only; Lane 5 folded RNA with no aniline treatment.  [Ru(bpy)32+, 
Co(NH3)5Cl2+], photolysis time: Lane 2, 50 µM, 500 µM, no photolysis; Lane 3, 50 µM, 0 
µM, 10 min; Lane 4, 0 µM, 50 µM, 10 min; Lane 5, 50 µM, 500 µM, 10 min; Lane 6, 10 
µM, 100 µM, 10 min; Lane 7, 25 µM, 250 µM, 10 min; Lane 8, 50 µM, 500 µM, 10 min; 
Lane 9, 100 µM, 1 mM, 10 min, Lane 10, 250 µM, 2.5 mM, 10 min; Lane 11, 50 µM, 500 
µM, 5 min; Lane 12, 50 µM, 500 µM, 15 min; Lane 13, Guanine ladder.   
 
1       3      5       7       9      11     13  
10/11
  39 
28-31 
25 
    42 
15/16 
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  126
  
Figure 3.9. Analysis of the preproinsulin splice variant hairpin RNA structure by RNase 
cleavage.  All lanes, [RNA] ~ 5 µM. Lane 1, folded RNA only.  Lane 2, alkaline hydrolysis 
ladder.  Lane 3, guanine Ladder.  Lanes 4-6, cytosine, uridine ladder.  [RNase], time: Lane 7, 
RNase A, 0.001 U, 5 min; Lane 8, RNase A, 0.001 U, 10 min; Lane 9, RNase T1, 1 U, 10 
min; Lane 10, RNase T1, 1 U, 15 min; Lane 11 RNase T1, 0.2 U, 5 min; Lane 12, RNase T1, 
0.2 U,10 min; Lane 13, RNase I, 0.1 U, 15 sec; Lane 14, RNase I, 0.01 U, 2 min; Lane 15, 
RNase I, 0.01 U, 2.5 min; Lane 16, RNase I, 0.01 U, 1 min; Lane 17, RNase V1, 0.1 U, 15 
min; Lane 18, RNase V1, 0.2 U, 10 min; Lane 19, RNase V1, 0.2 U, 15 min.           
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30/31 
15 
42/43 
47 
68 
75 
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Figure 3.10. Analysis of the preproinsulin splice variant hairpin RNA structure by 
Ru(tpy)(bpy)O2+ mediated guanine oxidation. All lanes, [RNA] ~ 0.75 µM. Lane 1, alkaline 
hydrolysis ladder.  Lane 2, guanine ladder.  Lane 3, RNase A, 0.001 U, 5 min.  Lane 4, 
RNase A, 0.001 U, 10 min.  Lane 5, RNase T1, 0.2 U, 10 min.  Lane 6, RNase I, 0.01 U, 2 
min.  Lanes 7-14, reaction time 5 min.  [RuO2+]: Lane 7, folded RNA without aniline 
treatment; Lane 8, folded RNA with aniline treatment; Lane 9, 25 µM; Lane 10, 50 µM; 
Lane 11, 100 µM; Lane 12, 150 µM; Lane 13, 200 µM; Lane 14, 250 µM. 
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Figure 3.11. Analysis of the preproinsulin splice variant hairpin RNA structure by guanine 
oxidation using the flash-quench technique.  Lanes 1-15, [RNA] ~ 0.7 µM.  Lane 1, alkaline 
hydrolysis ladder.  Lane 2, RNase A, 0.001 U, 10 min.  Lane 3, RNase T1, 0.2 U, 10 min. 
Lanes 4-8 controls: Lane 4, folded RNA with aniline treatment; Lane 5, no photolysis; Lane 
6, Ru(bpy)32+ oxidant only; Lane 7, Co(NH3)5Cl2+ quencher only; Lane 8 folded RNA with 
out aniline treatment.  [Ru(bpy)32+, Co(NH3)5Cl2+], photolysis time: Lane 5, 50 µM, 500 µM, 
no photolysis; Lane 6, 50 µM, 0 µM, 10 min; Lane 7, 0 µM, 50 µM, 10 min; Lane 8, 50 µM, 
500 µM, 10 min; Lane 9, 10 µM, 100 µM, 10 min; Lane 10, 25 µM, 250 µM, 10 min,; Lane 
11, 50 µM, 500 µM, 10 min; Lane 12, 100 µM, 1 mM, 10 min, Lane 13, 250 µM, 2.5 mM, 
10 min; Lane 14, 50 µM, 500 µM, 5 min; Lane 15, 50 µM, 500 µM, 15 min.   
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Figure 3.12. Effect of promazine and yohimbine on RNase cleavage of the native human 
preproinsulin hairpin RNA.  Lane 1, alkaline hydrolysis ladder.  Lane 2, guanine ladder.  
Lane 3, folded RNA only.  Lanes 4-8 and 14-18, RNase A, 0.001 U, 10 min. Lanes 9-13 and 
19-23, RNase T1, 0.2 U, 10 min.  [promazine]: Lane 4, 0 µM; Lane 5, 10 µM; Lane 6, 50 
µM; Lane 7, 100 µM; Lane 8, 2 mM; Lane 9, 0 µM; Lane 10, 10 µM; Lane 11, 50 µM; Lane 
12, 100 µM; Lane 13, 2 mM.  [yohimbine]: Lane 14, 0 µM; Lane 15, 10 µM; Lane 16, 50 
µM; Lane 17, 100 µM; Lane 18, 2 mM; Lane 19, 0 µM; Lane 20, 10 µM; Lane 21, 50 µM; 
Lane 22, 100 µM; Lane 23, 2 mM.
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Figure 3.13.  Effect of promazine and yohimbine on the RNase cleavage of the human 
preproinsulin splice variant hairpin RNA.  Lane 1, alkaline hydrolysis ladder.  Lane 2, 
guanine ladder.  Lane 3, folded RNA only.  Lanes 4-8 and 14-18, RNase A, 0.001 U, 10 min. 
Lanes 9-13 and 19-23, RNase T1, 0.2 U, 10 min.  [promazine]: Lane 4, 0 µM; Lane 5, 10 
µM; Lane 6, 50 µM; Lane 7, 100 µM; Lane 8, 2 mM; Lane 9, 0 µM; Lane 10, 10 µM; Lane 
11, 50 µM; Lane 12, 100 µM; Lane 138, 2 mM.  [yohimbine]: Lane 14, 0 µM; Lane 15, 10 
µM; Lane 16, 50 µM; Lane 17, 100 µM; Lane 18, 2 mM; Lane 19, 0 µM; Lane 20, 10 µM; 
Lane 21, 50 µM; Lane 22, 100 µM; Lane 23, 2 mM. 
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Figure 3.14. Effect of neomycin B and Hoechst 33258 on the RNase cleavage of the native 
human preproinsulin hairpin RNA.  Lane 1, alkaline hydrolysis ladder.  Lane 2, guanine 
ladder.  Lane 3, folded RNA only.  Lanes 4-8 and 14-18, RNase A, 0.001 U, 10 min. Lanes 
9-13 and 19-23, RNase T1, 0.2 U, 10 min.  [neomycin B]: Lane 4, 0 µM; Lane 5, 10 µM; 
Lane 6, 50 µM; Lane 7, 100 µM; Lane 8, 2 mM; Lane 9, 0 µM; Lane 10, 10 µM; Lane 11, 50 
µM; Lane 12, 100 µM; Lane 13, 2 mM.  [Hoechst 33258]: Lane 14, 0 µM; Lane 15, 10 µM; 
Lane 16, 50 µM; Lane 17, 100 µM; Lane 18, 2 mM; Lane 19, 0 µM; Lane 20, 10 µM; Lane 
21, 50 µM; Lane 22, 100 µM; Lane 23, 2 mM. 
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Figure 3.15.  Effect of neomycin B on RNase cleavage of the native preproinsulin hairpin 
RNA.  A) Quantitation of RNase A cleavage.  B) Quantitation of RNaseT1 cleavage.  Legend 
values indicate the final neomycin B concentration in the assay.  Data is representative of one 
trial.         
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Figure 3.16.  Effect of neomycin B on the RNase cleavage of the human preproinsulin splice 
variant hairpin RNA.  Lane 1, alkaline hydrolysis ladder.  Lane 2, guanine ladder.  Lane 3, 
folded RNA only.  Lanes 4-8, RNase A, 0.001 U, 10 min. Lanes 9-13, RNase T1, 0.2 U, 10 
min.  [neomycin B]: Lane 4, 0 µM; Lane 5, 10 µM; Lane 6, 25 µM; Lane 7, 50 µM; Lane 8, 
100 µM; Lane 9, 0 µM; Lane 10, 10 µM; Lane 11, 25 µM; Lane 12, 500 µM; Lane 13, 100 
µM.   
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Figure 3.17. Effect of neomycin B on RNase cleavage of the human preproinsulin splice 
variant hairpin RNA.  Quantitations were done using ImageQuantTM software.  Legend 
values indicate the final neomycin B concentration in the assay.  Data is representative of one 
trial.           
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Figure 3.18. Effect of neomycin B on guanine oxidation in the native preproinsulin hairpin 
RNA.  Lane 1, alkaline hydrolysis ladder.  Lane 2, guanine ladder.  Lane 3, folded RNA 
only, no aniline treatment. Lane 4, folded RNA only, with aniline treatment.  Lanes 5-10, 
[RuO2+] = 100 µM, reaction time 5 min. [neomycin B]:  Lane 5, 0 µM; Lane 6, 0.01 µM; 
Lane 7, 1 µM; Lane 8, 5 µM; Lane 9,10 µM; Lane 10, 50 µM.  
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Figure 3.19.  Effect of neomycin B on guanine oxidation using the RuO2+ assay for native 
human preproinsulin hairpin RNA.  Legend values indicate the final neomycin B 
concentration in the assay.  Quantitations were done using ImageQuantTM software.  Data is 
representative of one trial.  
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Figure 3.20.  Effect of neomycin B on guanine oxidation in the preproinsulin hairpin splice 
variant RNA.  Lane 1, alkaline hydrolysis ladder.  Lane 2, guanine ladder.  Lane 3, folded 
RNA only, no aniline treatment. Lane 4, folded RNA only, with aniline treatment.  Lanes 5-
10, [RuO2+] = 100 µM, reaction time 5 min.  [neomycin B]:  Lane 5, 0 µM; Lane 6, 0.01 µM; 
Lane 7, 1 µM; Lane 8, 5 µM; Lane 9,10 µM; Lane 10, 50 µM.  
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Figure 3.21.  Effect of neomycin B on guanine oxidation using the RuO2+ assay for human 
preproinsulin splice variant hairpin RNA.  Legend values indicate the final neomycin B 
concentration in the assay.  Quantitations were done using ImageQuantTM software.  Data is 
representative of one trial.   
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Figure 3.22. Effect of kanamycin B on the RNase cleavage of the native human 
preproinsulin hairpin RNA.  Lane 1, alkaline hydrolysis ladder.  Lane 2, guanine ladder.  
Lane 3, folded RNA only.  Lanes 4-8, RNase A, 0.001 U, 10 min. Lanes 9-13, RNase T1, 0.2 
U, 10 min.  [promazine]: Lane 4, 0 µM; Lane 5, 10 µM; Lane 6, 50 µM; Lane 7, 100 µM; 
Lane 8, 2 mM; Lane 9, 0 µM; Lane 10, 10 µM; Lane 11, 25 µM; Lane 12, 50 µM; Lane 13, 
100 µM.   
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Figure 3.23.  Effect of kanamycin B on RNase cleavage of the native human preproinsulin 
hairpin RNA.  A) Quantitation of RNase A cleavage.  B) Quantitation of RNaseT1 cleavage.  
Legend values indicate the final kanamycin B concentration in the assay. Data is 
representative of one trial.         
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Figure 3.24. Effect of kanamycin B on the RNase cleavage of the human preproinsulin splice 
variant hairpin RNA.  Lane 1, alkaline hydrolysis ladder.  Lane 2, guanine ladder.  Lane 3, 
folded RNA only.  Lanes 4-8, RNase A, 0.001 U, 10 min. Lanes 9-13, RNase T1, 0.2 U, 10 
min.  [kanamycin B]: Lane 4, 0 µM; Lane 5, 10 µM; Lane 6, 25 µM; Lane 7, 50 µM; Lane 8, 
100 µM; Lane 9, 0 µM; Lane 10, 10 µM; Lane 11, 25 µM; Lane 12, 50 µM; Lane 13, 100 
µM.   
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Figure 3.25.  Effect of kanamycin B on RNase cleavage of the human preproinsulin 
splice variant hairpin RNA.  Quantitations were done using ImageQuantTM software.  
Legend values indicate the final kanamycin B concentration in the assay.  Data is 
representative of one trial.           
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Figure 3.26. Effect of kanamycin B on guanine oxidation in the native preproinsulin hairpin 
RNA.  Lanes 5-10, [RuO2+] = 100 µM, reaction time 5 min.  Lane 1, alkaline hydrolysis 
ladder.  Lane 2, guanine ladder.  Lane 3, folded RNA only, no aniline treatment. Lane 4, 
folded RNA only, with aniline treatment. [kanamycin B]:  Lane 5, 0 µM; Lane 6, 0.01 µM; 
Lane 7, 1 µM; Lane 8, 5 µM; Lane 9,10 µM; Lane 10, 50 µM.   
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Figure 3.27.  Effect of kanamycin B on guanine oxidation using the RuO2+ assay for native 
human preproinsulin hairpin RNA.  Legend values indicate the final kanamycin B 
concentration in the assay.  Quantitations were done using ImageQuantTM software.  Data is 
representative of one trial. 
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Figure 3.28. Effect of kanamycin B on guanine oxidation in the preproinsulin hairpin splice 
variant RNA.  Lane 1, alkaline hydrolysis ladder.  Lane 2, guanine ladder.  Lane 3, folded 
RNA only, with aniline treatment. Lane 4, folded RNA only, with out aniline treatment. 
Lanes 5-10, [RuO2+] = 100 µM, reaction time 5 min.  [kanamycin B]:  Lane 5, 0 µM; Lane 6, 
0.01 µM; Lane 7, 1 µM; Lane 8, 5 µM; Lane 9,10 µM; Lane 10, 50 µM.  
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Figure 3.29.  Effect of kanamycin B on guanine oxidation using the RuO2+ assay for 
human preproinsulin splice variant hairpin RNA.  Legend values indicate the final 
kanamycin B concentration in the assay.  Quantitations were done using 
ImageQuantTM software.  Data is representative of one trial.   
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Figure 3.30. Effect of Hoechst 33258 on the RNase cleavage of the human preproinsulin 
splice variant hairpin RNA.  Lane 1, alkaline hydrolysis ladder.  Lane 2, guanine ladder.  
Lane 3, folded RNA only.  Lanes 4-8, RNase A, 0.001 U, 10 min. Lanes 9-13, RNase T1, 0.2 
U, 10 min.  [Hoechst 33258]: Lane 4, 0 µM; Lane 5, 10 µM; Lane 6, 50 µM; Lane 7, 100 
µM; Lane 8, 2 mM; Lane 9, 0 µM; Lane 10, 10 µM; Lane 11, 50 µM; Lane 12, 100 µM; 
Lane 13, 2 mM.   
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Figure 3.31. Effect of hygromycin B on the RNase cleavage of the native human 
preproinsulin hairpin RNA.  Lane 1, alkaline hydrolysis ladder.  Lane 2, guanine ladder.  
Lane 3, folded RNA only.  Lane 4, RNase A, 0.001 U, 10 min. Lanes 5-9, RNase T1, 0.2 U, 
10 min.  [hygromycin B]: Lane 4, 2 mM; Lane 5, 0 µM; Lane 6, 10 µM; Lane 7, 50 µM; 
Lane 8, 100 µM; Lane 9, 2 mM. 
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Figure 3.32. Effect of hygromycin B on the RNase cleavage of the human preproinsulin 
splice variant hairpin RNA.  Lane 1, alkaline hydrolysis ladder.  Lane 2, guanine ladder.  
Lane 3, folded RNA only.  Lanes 4-8, RNase T1, 0.2 U, 10 min.  [hygromycin B]: Lane 4, 0 
µM; Lane 5, 10 µM; Lane 6, 50 µM; Lane 7, 100 µM; Lane 8, 2 mM.  
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Figure 3.33. Effect of neomycin B on guanine oxidation using the flash-quench technique in 
the preproinsulin hairpin splice variant RNA.  An increase in the concentration of small 
molecule caused an increase in the amount of guanine oxidation, and resulting RNA 
cleavage.  Lane 1, alkaline hydrolysis ladder.  Lane 2, guanine ladder.  Lane 3, folded RNA 
only, with aniline treatment. Lanes 4-9, [Ru(bpy)32+, Co(NH3)5Cl2+] = 100 µM, 1mM; 
reaction time 5 min.  [neomycin B]:  Lane 4, 0 µM; Lane 5, 0.01 µM; Lane 6, 1 µM; Lane 7, 
5 µM; Lane 8,10 µM; Lane 9, 50 µM.  
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Figure 3.34.  In vitro translation assay to determine the effect of neomycin B and kanamycin 
B on protein translation.  [35S]methionine SDS-PAGE gel depicting translation of (A) native 
preproinsulin mRNA in the presence of kanamycin B (B) native preproinsulin mRNA in the 
presence of neomycin B, (C) preproinsulin splice variant mRNA in the presence of 
kanamycin B, and (D) preproinsulin splice variant mRNA in the presence of neomycin B. 
[mRNA]= 1ug.  [promazine]: Lane 1, 0 µM; Lane 2, 1 µM; Lane 3, 10 µM; Lane 4, 40 µM; 
Lane 5, 80 µM. 
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Figure 3.35.  Effect of neomycin B and kanamycin B on human preproinsulin mRNA 
translation in cell-free extracts as measured by incorporation of [35S]methionine.  Data are 
representative of at least three different trials on at least two separate preparations of RNA.  
These results are expressed as a percentage of the control (no small molecule added), and the 
error bars represent standard deviation.     
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Figure 3.36.  Effect of promazine and yohimbine on human preproinsulin mRNA translation 
in cell-free extracts as measured by incorporation of [35S]methionine.  Data are representative 
of at least three different trials on at least two separate preparations of RNA.  These results 
are expressed as a percentage of the control (no small molecule added), and the error bars 
represent standard deviation.     
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Figure 3.37. Effect of neomycin B and kanamycin B on luciferase mRNA translation in cell-
free extracts as measured by incorporation of [35S]methionine.  Data are representative of at 
least three different trials.  These results are expressed as a percentage of the control (no 
small molecule added), and the error bars represent standard deviation.   
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